

THE UNIVERSITY OF BRITISH COLUMBIA

Curriculum Vitae for Faculty Members

Date: January 2015

1. **SURNAME:** McCormack **FIRST NAME:** James
MIDDLE NAME: Philip
2. **DEPARTMENT/SCHOOL:**
3. **FACULTY:** Faculty of Pharmaceutical Sciences
4. **PRESENT RANK:** Professor **SINCE:** 2002
5. **POST-SECONDARY EDUCATION**

| University or Institution | Degree | Subject Area | Dates |
|--------------------------------------|-----------|-------------------|-------|
| University of British Columbia | B.Sc. | Biochemistry | 1979 |
| University of British Columbia | B.Sc. | Pharmacy | 1982 |
| UBC/ Lion's Gate Hospital | Residency | Hospital Pharmacy | 1983 |
| Medical University of South Carolina | Pharm.D. | Clinical Pharmacy | 1986 |

Special Professional Qualifications

6. **EMPLOYMENT RECORD**

(a) **Prior to coming to UBC**

| University, Company or Organization | Rank or Title | Dates |
|-------------------------------------|---------------|--------|
| London Drugs | Pharmacist | 1982-3 |

(b) **UBC**

| Rank or Title | Dates |
|--|----------------|
| Assistant Professor | 1986-1994 |
| Associate Professor | 1994 – 2002 |
| Professor | 2002 – present |
| Clinical Pharmacist, St. Paul's Hospital * | 1986 – 2005 |
| Member of the Therapeutics Initiative ** | 1994 – 2009 |

*My role at St. Paul's Hospital up until 1994 included being a clinical pharmacist on an internal medicine ward, education and the residency coordinator (2 years) – from 1994 until 2005 my primary was education and involvement with the residency program

** My role at the Therapeutics Initiative up until 2009 included being a member of the Executive and a member of the Education Working group

(c) **Date of granting of tenure at U.B.C.:**

July 1994

7. **LEAVES OF ABSENCE**

| University, Company or Organization at which Leave was taken | Type of Leave | Dates |
|--|---------------|---------------------|
| UBC | Sabbatical | July 2013-June 2014 |

8. TEACHING**(a) Areas of special interest and accomplishments**

General - evidence based healthcare, critical thinking, critical appraisal, clinical trial evaluation, shared-informed decision making, rational prescribing

Therapeutics - asthma, chronic obstructive pulmonary disease, hypertension, hyperlipidemia, peptic ulcer disease, gastroesophageal reflux, sports injuries, infectious diseases

Pharmacokinetics – drug dosing, renal disease, therapeutic drug monitoring evidence, clearance and volume of distribution concepts

(b) Courses Taught at UBC – 1994-2012

| Course Number | Credit | Class Size | Lecture Hours | | | | | | | | | | | | | | | | | |
|-------------------|--------|------------|---------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| | | | 94/95 | 95/96 | 96/97 | 97/98 | 98/99 | 99/00 | 00/01 | 01/02 | 02/03 | 03/04 | 04/05 | 05/06 | 06/07 | 07/08 | 08/09 | 09/10 | 10/11 | 11/12 |
| Phar 100 | 6 | 120 | | | | | | | 3 | 4 | | | | | | | | | | |
| Phar 301 | 5 | 120 | | | | | | | 1 | 2 | 3 | 3 | 3 | | | | | | | |
| Phar 380 | 6 | 120 | 7 | 4 | 6 | 7 | 7 | 7 | 8 | 5 | 6 | 6 | 6 | | | | | | | |
| Phar 385 | 6 | 120 | 4 | 4 | 4 | 3 | 5 | 4 | 2.5 | 4 | 4 | 4 | 4 | | | | | | | |
| Phar 399 | | | | | | | | | | | | | 2 | | | | | | | |
| Phar 407 | 3 | 20 | | | | 2 | | | | | | | | | | | | | | |
| Phar 408 | 4 | 20 | 15* | 19* | 15* | 3 | | 3.5 | 2.5 | | | | | | | | | | | |
| Phar 440 | 3 | 20 | 2 | 2 | 2 | | | | | | | | | | | | | | | |
| Phar 450 | | | | | | | | | | | | | | | | | | | | |
| Phar 455 | 3 | 30 | | | | 2 | 2 | 2 | 2 | 2 | 2 | 2 | | | | | | | | |
| Phar 480 | 6 | 120 | 4 | 4 | 3 | 3 | 4* | 3* | 3* | 3 | 6 | 3 | 3 | 4 | | | | | | |
| Phar 490 | 3 | 25 | | | | 1 | 1 | 1 | 1 | 1 | | | | | | | | | | |
| Phar 498 | | | | | | | | | | | | | | 2 | | | | | | |
| Phar 501 | 12 | 6 | 14 | 17 | 17 | 24 | 24 | 24 | 24 | | | 22 | | | | | | | | |
| Phar 503 | 2-12 | | | 2** | 2** | 2** | 2** | 2** | 2** | | | | | | | | | | | |
| Phar 508 | 4 | 6 | 11* | 13* | 10* | 7 | 9 | 8 | 6 | | | 6 | | | | | | | | |
| Phar 535 | 2 | 6 | 1 | | 2 | | | | | | | 1.5 | | | | | | | | |
| Nurs | | 30 | | | | | 3 | | | | | | | | | | | | | |
| Phar 554 | 3 | 6 | | | | 1.5 | 1.5 | 1.5 | 1.5 | | | 1.5 | | | | | | | | |
| Rhsc 301 | 3 | 60 | | | | | 2 | 2 | 2 | 2 | 2 | 2 | | | | | | | | |
| Bioc 448 | 3 | 15 | | | | | | 2 | 2 | 2 | 2.5 | 2.5 | | | | | | | | |
| Phar 299 | 3 | 140 | | | | | | | | | 6 | 8 | 4 | 3 | 2 | 3 | 2 | 2 | | 4 |
| Phar 351 | 2 | 140 | | | | | | | | | | | 8 | 9 | 6 | 9 | 7 | 7 | 7 | 7 |
| Phar 451 | | | | | | | | | | | | | | | 5 | 4 | 5 | 5 | 5 | 5 |
| Phar 462 | 1 | 140 | | | | | | | | | | | | | 2 | 4 | 2 | 2 | 2 | 2 |
| Phar 498 | 3 | 135 | | | | | | | | | | | | 2 | 2 | 0 | 1 | 0 | 0 | 0 |
| Phar 501 | 12 | 6 | | | | | | | | 26.5 | 26 | | 17 | 19 | 19 | 21 | 19 | 16 | 15 | 15 |
| Phar 508 | 4 | 9 | | | | | | | | 8 | 8 | | 6 | 7 | 6 | 7 | 4 | 4 | 4 | 4 |
| Phar 535 a, b, c | 2 | 12 | | | | | | | | 4 | 4 | | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 |
| CP3 | | 30 | | | | | | | | | | | 6 | 18 | 2.5 | 5 | 6 | 6 | 6 | 6 |
| Phar 554 | 3 | 6 | | | | | | | | 1.5 | | | 1.5 | 1.5 | 3 | 3 | 1.5 | 1.5 | 1.5 | 1.5 |
| Hosp res | | | | | | | | | | | | | | | 5 | 5 | 5 | 5 | 5 | 5 |
| Medicine 3rd year | | | | | | | | | | | | | | | 2.5 | | 1.5 | 1.5 | 3 | 3 |
| Nurs 507 | 3 | 60 | | | | | | | | | | | 9 | 3 | | | | | | |
| TOTAL | | | 58 | 63 | 59 | 53.5 | 58.5 | 58 | 58.5 | 65 | 69.5 | 69.5 | 71.5 | 81.5 | 57 | 64 | 56 | 52 | 50.5 | 54.5 |

| Course Number | Tutorial Hours | | | | | | | | | | | | | | | | | | |
|-------------------|----------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|----------|----------|----------|--|
| | 94/95 | 95/96 | 96/97 | 97/98 | 98/99 | 99/00 | 00/01 | 01/02 | 02/03 | 03/04 | 04/05 | 05/06 | 06/07 | 07/08 | 08/09 | 09/10 | 10/11 | 11/12 | |
| Phar 380 | 14 | 14 | 12 | 12 | 12 | 12 | 12 | 12 | 14 | 10 | 6 | | | | | | | | |
| Phar 385 | 4 | 2 | 2 | 2 | 2 | | 2 | 2 | 2 | 2 | | | | | | | | | |
| Phar 399 | | | | | | | | | | | 13 | | | | | | | | |
| Phar 480 | 2 | 2 | 2 | 6 | 4 | | | 4 | 4 | 4 | 2 | 4 | | | | | | | |
| Phar 498 | | | | | | | | | | | | 30 | | | | | | | |
| Phar 508 | | | | | 2 | 2 | 2 | | | 1 | | | | | | | | | |
| Phar 535 | | | | | | 2 | 2 | | | 4 | | | | | | | | | |
| Phar 299 | | | | | | | | | 21 | 25 | | | | 9 | | | | 9 | |
| Phar 498 | | | | | | | | | | | | | 24 | 15 | 15 | | | | |
| Medicine 3rd year | | | | | | | | | | | | | | | 2 | 2 | | | |
| TOTAL | 32 | 18 | 16 | 20 | 20 | 16 | 18 | 18 | 41 | 46 | 23 | 34 | 14 | 24 | 17 | 2 | 0 | 9 | |

* course coordinator during this time, ** indicates the number of 1-month clinical rotations supervised for the Pharm D program

(c) Present teaching responsibilities

Coordinator Phar 351, Phar 535 B/C, and Phar 501 (respiratory) – I also teach in Phar 299, 451, 462, 501, 508, 554, CP3, pharmacy practice residency program, family practice residency program, and 3rd year medicine.

(d) Graduate Students Supervised 1994-2001

| Student Name | Program Type | Year | | Principal Supervisor | Co-Supervisor(s) |
|---|--------------|-------|--------|----------------------|---|
| | | Start | Finish | | |
| Donna Buna, Renette Dunn, John Forster-Coull, Jane Gillis*#, Mary Ann Lindsay#, John MacReady, Leslie Phillips, Ric Procyshyn#, Linda Sulz, Jane DeLemos, Brenda Osmond*, Margaret Ackman, Rubina Sunderji#, Terryn Naumann, Fawziah Marra, Carlo Marra#, Peter Loewen, Cathy MacDougall#, Suzanne Malfair, Robin O'Brien, Alan Low#, Wendy Leong#, Elaine Kam#, Shallen Letwin | Pharm D | 1991 | 1996 | Glenda Meneilly | * - indicates Pharm D faculty advisor |
| Ema Ferreira, David Gardner*#, Patricia Gerber#, Wendy Gordon, Christine Hughes, Adil Virani | Pharm D | 1995 | 1997 | Peter Jewesson | # - indicates supervised or co-supervised Pharm D rotation(s) |
| Marie-France Beauchesne*, Dana Leigh Cole*, Zahra Esmail*#, Bruce Lange, Agnes Lo, Peter Zed# | Pharm D | 1996 | 1998 | Peter Jewesson | |
| Robert Balen, Mario De Lemos, Anne Nguyen*, Kari Olson*, Sophie Robert, Priti Thomas# | Pharm D | 1997 | 1999 | Peter Jewesson | |
| Sandy Dubyk, Eric Lun, Tania Mysak, Shannon Sinclair#, Kerry Wilbur | Pharm D | 1998 | 2000 | Peter Jewesson | |
| Lily Cheng, Sean Gorman, Leela John, Tim Lau, Payal Patel, Colette Raymond*# | Pharm D | 1999 | 2001 | Peter Jewesson | |
| Bitu Bateni | M Sc | 1999 | | Steve Shalansky | James McCormack |

9. SCHOLARLY AND PROFESSIONAL ACTIVITIES

(a) **Areas of special interest and accomplishments**

Much of my career has been devoted to the dissemination of information about rationale drug use and the concepts of evidence-based health care. My accomplishments in this area are shown by my academic publications, the two drug therapy texts which I have edited, the 300 + presentations I have given since 1994, a website that I helped develop which has received international recognition www.ti.ubc.ca and a developer of one of the most popular medical podcasts (Therapeutics Education Collaboration) in Canada and worldwide - therapeuticseducation.org My scholarly activities also include the development and evaluation of educational interventions designed to improve drug use. I develop simple approaches and methods to help guide physicians, pharmacists and the public in making rational decisions about drug therapy. The focus of the message is optimizing patient benefit using interactive techniques to demonstrate evidence based and cost-effective drug use. In addition, I attempt to get clinicians to understand the concepts of risk reductions in clinical trials as results are most often presented as a relative risk reduction. I have also continually promoted the concepts of shared-informed decision-making. As well, there is significant evidence that commonly recommended drug doses are often excessive and I attempt to give clinicians the tools to determine the best dose of drugs for individual patients.

(b) **Research or equivalent grants (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC)).**

| Granting Agency | Subject | COMP | \$ | Year | Principal Investigator | Co-Investigator(s) |
|---|--|------|------------|-------------|------------------------------------|--|
| Vancouver Foundation | A double blind comparison of regularly scheduled oral morphine vs intermittent intramuscular therapy in the treatment of postsurgical pain secondary to total hip arthroplasty | C | 35,000 | 1989 | McCormack JP | Warriner B Levine M |
| Knoll Pharmaceuticals | The efficacy, safety, and pharmacokinetics of regularly scheduled oral hydromorphone in the treatment of postsurgical pain | NC | 10,500 | 1990 | McCormack JP | Warriner B Levine M |
| WB Saunders | Drug Therapy Decision Making Guide. A contract with W.B. Saunders to produce this book | C | 8,000 | 1990 | McCormack JP | |
| Roche | Flumazenil reversal of benzodiazepine induced anesthesia. | NC | 20,000 | 1991 | McCormack JP Warriner B | |
| St. Paul's Hospital Advanced Education Fund | Patient counselling profile service | C | 3,500 | 1992 | McCormack JP | |
| NHRDP | Evaluation of Drug Substitution Policy's Impact on Seniors and Senior's Impact on Drug Policy | C | 495,000 | 1994 | Maclure M | McCormack JP Chappell N Rangno R Brunt H Thompson M Mullett J |
| Ministry of Health | Therapeutics Initiative (a program grant that funds the entire Therapeutics Initiative) | NC | 526,700/yr | 1994 - 1999 | Wright J | McCormack JP van Breemen C Rangno R |
| Health Transition Fund | Canada Drug Guide: A pilot study | C | 400,000 | 1998 | McCormack JP Levine M Gray J | |
| Lions Gate Healthcare Research Foundation grant | Can Patients Encourage Physicians to Share Evidence-Based Decision Information? | C | 25,000 | 1999 | Godolphin W | McCormack JP McHendry R |
| Ministry of Health | Therapeutics Initiative (a program grant that funds the entire Therapeutics Initiative) | NC | 725,000/yr | 2000 - 2009 | Wright J | McCormack JP van Breemen C Rangno R Whiteside C |

| | | | | | | |
|--|---|---|---------|------|---------------|---|
| David Collins Dawson Endowment Fund | Centre for Outcomes Research and Evaluation | C | 210,000 | 2000 | Fielding DW | McCormack JP Carleton BC Levine M Ensom MHH Soon JA Paluck ECM |
| Office of Consumer Affairs at Industry Canada | An Analysis of Canadian Media Reporting of Pharmaceuticals: How well is the Media Reporting the Good, the Bad and the Ugly of New Drugs | C | 35,305 | 2001 | Alan Cassels | McCormack JP Mintzes B Cole C |
| Industry Canada, Office of Consumer Affairs | Media Doctor in the Canadian Context: Assessing an audit and feedback mechanism to improve the quality of medical reporting in Canada | C | 67,965 | 2005 | Alan Cassels | McCormack JP |
| Teaching, Learning, and Enhancement Fund | Developing a patient-centred Pharmacists Clinic to provide an enriched experiential learning program for pharmacy students | C | 123,700 | 2012 | Tessa Nicholl | Liu R Low A Price I McCormack JP |
| Alberta Medical Association (via Toward Optimized Practice) | Knowledge Translation Program - Simplified Lipid Pathway (1.5 years) | C | 55,000 | 2014 | Mike Allan | McCormack J |

(d) Invited Presentations

* identifies a three to four hour interactive small group (5-15 participants) seminar for physicians and pharmacists done in conjunction with Dr. Robert Rangno. These seminars were part of an ongoing traveling roadshow of the Therapeutics Initiative. Topics discussed varied, depending on the needs of the group, but typically included discussions about evidence-based healthcare and the rationale drug therapy of high blood pressure, type 2 diabetes, joint pain, elevated cholesterol, heart failure, antibiotics, and new data on old drugs

** identifies a two hour, typically large group (50 -150) seminar, for patients done in conjunction with Dr. Robert Rangno. Topics discussed included drugs for joint pain, the risks and benefits of treating high blood pressure and high cholesterol and evidence-based health care

1986

1. J. McCormack. Vancomycin Pharmacokinetics in Adults. Medical Staff, St. Paul's Hospital, Vancouver. September 1986
2. J. McCormack. Drug and Non Drug treatment of Hypertension. School Board Community Education Department, Burnaby, BC. October 1986
3. J. McCormack. Captopril vs Enalapril in the treatment of congestive heart failure and hypertension. Clinical Seminar U.B.C., Vancouver, BC. November 1986
4. J. McCormack. Captopril vs Enalapril. Angiotensin converting enzyme inhibitors in the treatment of hypertension and congestive heart failure. Merck-Frosst Seminar, Vancouver, BC. November 1986

1987

5. J. McCormack. Drug and Non Drug Treatment of Hypertension, School Board Community Education Department, Burnaby, BC. May 1987
6. J. McCormack. Treatment of Methicillin-resistant Staphylococcal Infections: Focus on Vancomycin - Pharmacokinetics of Vancomycin in Adults. Health Sciences Centre Hospital Conference, Vancouver, BC. May 1987
7. J. McCormack. Imipenem: Now that we've got it, how do we use it? Canadian Society of Hospital Pharmacists New drugs seminar, Vancouver. September 1987
8. J. McCormack. A rational approach to drug use in the treatment of peptic ulcer disease. Merck-Frosst seminar, Vancouver, BC. November 1987
9. J. McCormack. Medical Management of Hypertension. Continuing Education, Surrey. December 1987

1988

10. J. McCormack. Medical Management of Hypertension. Audio Conference and Continuing Pharmacy Education, U.B.C. Vancouver, BC. April 1988
11. J. McCormack. Drug and Non Drug Treatment of Hypertension. School Board Community Education Department, Burnaby, BC. September 1988

1989

12. J. McCormack. Hypertension: Home Blood Pressure Monitoring, Oral Antibiotics in Community Practice. Continuing Pharmacy Education, Terrace, BC. 1989
13. J. McCormack. Medical Management of High Blood Pressure. Continuing Pharmacy Education, Sechelt, BC. 1989

1990

14. J. McCormack. Oral morphine in the Treatment of post-surgical Pain. Medical Grand Rounds, Vancouver, BC. 1990
15. J. McCormack. Oral morphine in the Treatment of post-surgical Pain. Clinical Pharmacology Conference, Vancouver BC. 1990
16. J. McCormack. Treatment of post-surgical Pain with Oral Morphine. Faculty Seminar, Vancouver BC. 1990
17. J. McCormack. IV antibiotic review - Consideration for cost effective use. Continuing Pharmacy Education, Prince George, BC. 1990
18. J. McCormack. Risk factors in the development of cardiovascular disease. A rational approach. Merck-Frosst seminar, Vancouver BC. November 1990

1991

19. J. McCormack. Therapeutic tips for the treatment of hypertension and congestive heart failure. Continuing Education for nurses, pharmacists, and general practitioners, Vancouver, BC. January/February 1991
20. J. McCormack. DNS - do not substitute or difference not significant. Clinical Pharmacology Conference, Vancouver, BC. April 1991
21. J. McCormack. Therapeutic tips to make your life easier. General practitioners Grand Rounds, St Paul's Hospital, Vancouver BC. April 1991
22. J. McCormack. DNS - do not substitute or difference not significant. Clinical Pharmacology Rounds, Vancouver, BC. May 1991
23. J. McCormack. Aminoglycoside levels - A useful therapeutic tool or a waste of time? DPIC Rounds St. Paul's Hospital, Vancouver BC. June 1991
24. J. McCormack. Aminoglycoside levels - A useful therapeutic tool or a waste of time? Pharm.D. Rounds, UBC, Vancouver BC. September 1991
25. J. McCormack. The use of regularly scheduled oral morphine in the treatment of post-surgical pain. PMAC/MRC Research Day. Montreal, QB. October 1991

1992

26. J. McCormack. The use of regularly scheduled oral morphine in the treatment of post-surgical pain. Nursing Rounds, Vancouver, BC. January 1992.
27. J. McCormack. Aminoglycoside levels - A useful therapeutic tool or a waste of time? Clinical Pharmacy Rounds St. Paul's Hospital, Vancouver BC. February 1992.
28. J. McCormack. The impact of the "Cholesterol Quest" on prescribing lipid lowering drugs to patients over 65 in BC. Clinical Pharmacology Conference, Vancouver, BC. April, 1992

1993

29. J. McCormack. Hypertension - Why and how to treat. Clinical Pharmacy Rounds, St Paul's Hospital, Vancouver BC. January 1993
30. J. McCormack. Absolute versus relative risk reduction and its implication in decision-making. Clinical Pharmacy Rounds. St Paul's Hospital, Vancouver, BC. February 1993
31. J. McCormack. The use of lipid-lowering agents. Continuing Medical Education Teleconference, Vancouver, BC. April 1993
32. J. McCormack. I came to bury drugs not to praise them. Clinical Pharmacology Conference, Vancouver, BC. April 1993
33. J. McCormack. The use of lipid-lowering drugs: Is relative reduction really relevant? Continuing Pharmacy Education, Vancouver, BC. May 1993
34. J. McCormack. Pharmaceutical Care - Are we already doing it? Clinical Pharmacy Rounds, St Paul's Hospital, Vancouver, BC. May 1993
35. J. McCormack. Pharmaceutical Care - A real-life case study. Clinical Pharmacy Rounds, St Paul's Hospital, Vancouver BC. May 1993
36. J. McCormack. CPS dosing is not for your patient, DNS - do not substitute or difference not significant, I came to bury drugs not to praise them. Health Care Conference, Justice Institute, Vancouver, BC. May 1993
37. J. McCormack. DNS - do not substitute or difference not significant, I came to bury drugs not to praise them. Medical Grand Rounds, Vancouver BC. May 1993
38. J. McCormack. The use of lipid-lowering drugs: Is relative reduction really relevant? I came to bury drugs not to praise them. Continuing Medical Education, Trail BC. May 1993
39. J. McCormack. The use of lipid-lowering drugs: Is relative reduction really relevant? I came to bury drugs not to praise them. Continuing Medical Education, Powell River BC. June 1993
40. J. McCormack. Sensible use of common drugs used in family practice. Continuing Medical Education, Vancouver BC. June 1993
41. J. McCormack. The use of lipid-lowering agents in a population base of 400,000 patients over the age of 65. Royal College of Physicians and surgeons meeting, Vancouver BC. September 1993
42. J. McCormack. The CPS dose is not for your patient. Faculty Seminar, Vancouver, BC. November 1993
43. J. McCormack. Absolute versus relative risk reduction and the CPS dose is not for your patient. Annual General Meeting of the BC. Branch CSHP, Vancouver, BC. November 1993

1994

44. J. McCormack. Usefulness of calcium channel blockers: marketing versus reality. Continuing Medical Education Teleconference, Vancouver BC. February 1994
45. J. McCormack. Use of upper gastrointestinal agents. Continuing Medical Education Teleconference, Vancouver, BC. February 1994
46. J. McCormack. Pharmacological Jeopardy. Faculty Seminar, Vancouver, BC. March 1994
47. J. McCormack. Justifying cardiovascular risk interventions for primary prevention Clinical Pharmacology Conference, Vancouver, BC. April 1994
48. J. McCormack. The appropriate use of NSAIDs . Workman's Compensation Board, Vancouver, BC. April 1994
49. J. McCormack. Justifying cardiovascular risk interventions for primary prevention /An update (1992-1993) on the use of lipid-lowering agents in 400,000 patients over the age of 65. Canadian Forum on Pharmacoepidemiology, Vancouver, BC. April 1994
50. J. McCormack. Oral Antibiotics - The role of new and old agents. Continuing Pharmacy Education, Vancouver, BC. April 1994
51. J. McCormack. Doses of Drugs and Risk Reduction. St Paul's Pharmacy Technicians, Vancouver, BC May 1994
52. J. McCormack. Hypertension, hypercholesterolemia, and risk reduction. Family practice rounds, Vancouver, BC. June 1994
53. J. McCormack. Royal College of Physicians and surgeons meeting - An update on the use of lipid-lowering agents in a population base of 400,000 patients over the age of 65. (Paper Presentation). Toronto, ON Sept 1994
54. J. McCormack. The appropriate use of NSAIDs. Workman's Compensation Board, Richmond, BC. September 1994
55. J. McCormack. *Drug Therapy Decision Making Physician and Pharmacist Seminar, (**7 separate seminars**) Nelson, Victoria, Prince Rupert, Hazelton, Kitimat, Prince George, Williams Lake, BC, September- November 1994

56. J. McCormack. The appropriate use of NSAIDs. St Paul's Medical Residents, Vancouver, BC. December 1994

1995

57. J. McCormack. ****Drugs for Joint pain - Patient Seminar, (8 separate seminars)** Abbotsford, Kelowna, Penticton, Chilliwack, Courtenay, Qualicum Beach, Nanaimo, Victoria. 1995
58. J. McCormack. ***Drug Therapy Decision Making Physician and Pharmacist Seminar, (18 separate seminars)** Abbotsford, Vernon, Port Alberni, Kelowna, Chilliwack, Campbell River, Courtenay, Duncan, Nanaimo, Victoria, Yellowknife, Cranbrook, Trail, Castlegar, Sechelt, Whitehorse, Salmon Arm, Kamloops, BC 1995
59. J. McCormack. Risk Reduction for Cardiovascular Disease Heart and Stroke Foundation Annual Meeting. Vancouver, BC. February 1995
60. J. McCormack. Therapeutics Initiative - What is it and what can it do for you? BC Pharmacy Association Monthly morning meeting, Vancouver, BC. March 1995
61. J. McCormack. Evidence-based Medicine. Senior Medical Residents Annual Meeting, Vancouver, BC. April 1995
62. J. McCormack. Salmeterol - New Drugs Update (BC CSHP), Vancouver, BC. April 1995
63. J. McCormack. Drug Therapy Decision Making Annual Course, Vancouver, BC. Apr 1995
64. J. McCormack. Drug Therapy Decision Making Family practice rounds. Vancouver, BC. June 1995
65. J. McCormack. Risk Reduction for Cardiovascular Disease. St Paul's Medical Grand Rounds, Vancouver, BC. July 1995
66. J. McCormack. ****Heart Attack and Strokes: What are the risks and can they be reduced with prescription drugs - Patient Seminar, (2 separate seminars)** Kamloops, Mission, BC. 1995

1996

67. J. McCormack. ****Heart Attack and Strokes: What are the risks and can they be reduced with prescription drugs - Patient Seminar, (5 separate seminars)** White Rock, Vancouver, Burnaby, Richmond, New Westminster BC. 1996
68. J. McCormack. ***Drug Therapy Decision Making Physician and Pharmacist Seminar, (5 separate seminars)** Powell River, Vancouver, Langley, Richmond, Langley, BC. 1996
69. J. McCormack. OTCs - What works, what doesn't - Drug Therapy Decision Making Annual Course, Vancouver, BC. April 1996
70. J. McCormack. NSAID myths: a) sports injuries, b) misprostol combinations. Drug Therapy Decision Making Course, Vancouver, BC. April 1996
71. J. McCormack. Internal Medicine for the Practitioner Course - Clinical Pharmacology, St.Paul's Hospital Vancouver, BC. May 1996
72. J. McCormack. Pharmaceutical Care - 50th Anniversary Faculty of Pharmaceutical Sciences Continuing Education, Vancouver. May 1996
73. J. McCormack. Risk reduction for cardiovascular disease - what are the risks and benefits. Department of Internal Medicine , Waterfront Hotel, Vancouver, BC. June 1996
74. J. McCormack. Drug beliefs. St Paul's Medical Grand Rounds, Vancouver, BC. July 1996
75. J. McCormack. Drug beliefs. Faculty Seminar, Vancouver, BC. September 1996
76. J. McCormack. ****Drugs for Joint pain - Patient Seminar, Langley, BC. October 1996**
77. J. McCormack. Understanding the numbers - drug beliefs. Continuing Medical Education Teleconference, Vancouver. November 1996

1997

78. J. McCormack. ****Heart Attack and Strokes: What are the risks and can they be reduced with prescription drugs - Patient Seminar, (2 separate seminars)** Abbotsford, Victoria, BC. 1997
79. J. McCormack. ***Drug Therapy Decision Making Physician and Pharmacist Seminar, (2 separate seminars)** Abbotsford, Vancouver, BC. 1997
80. J. McCormack. Train the trainer - Physician and Pharmacists day-long seminar, Vancouver, BC. April 1997
81. J. McCormack. The side effects of telling patients about side effects. Drug Therapy Decision Making Annual Course, Vancouver, BC. April 1997
82. J. McCormack. Co-coordinator - Drug Therapy Decision Making Annual Course - Physician and Pharmacist 2-day drug therapy course. Vancouver, BC. April 1997
83. J. McCormack. ****Drugs for Joint pain - Patient Seminar, Burnaby, BC. October 1997**
84. J. McCormack. The side effects of telling patients about side effects. St. Paul's Hospital Grand Rounds, Vancouver, BC. September 1997
85. J. McCormack. The side effects of telling patients about side effects. Burnaby Hospital Grand Rounds, Burnaby BC. September 1997
86. J. McCormack. The side effects of telling patients about side effects. Faculty Seminar, Vancouver, BC. September 1997

1998

87. J. McCormack. Bioequivalence of NTI drugs: Does it make a difference in clinical practice. Forum on narrow therapeutic index drugs, Vancouver, BC. January 1998
88. J. McCormack. ****Heart Attack and Strokes: What are the risks and can they be reduced with prescription drugs - Patient Seminar, (6 separate seminars)** Vancouver, New Westminster, North Vancouver, Richmond, Burnaby, White Rock, BC. 1998
89. J. McCormack. ***Drug Therapy Decision Making Physician and Pharmacist Seminar, (9 separate seminars)** Vancouver, New Westminster, Richmond, White Rock, Vancouver, Vancouver, Surrey, Burnaby, Victoria, BC. 1998
90. J. McCormack. Harnessing the energy of placebo without deception. Drug Therapy Decision Making Annual Course, Vancouver, BC. April 1998
91. J. McCormack. Co-coordinator - Drug Therapy Decision Making Annual Course - Physician and Pharmacist 2-day drug therapy course. Richmond, BC. April 1998
92. J. McCormack. Pantoprazole, atorvastatin, carvedilol, donepezil. Continuing Medical Education Teleconference. Vancouver, BC. April 1998
93. J. McCormack. Explaining risks to patients. Canadian Society of Hospital Pharmacists Workshop, Vancouver, BC. September 1998

94. J. McCormack. Explaining risks in the media. American Medical Writers Association Annual Meeting, Vancouver, BC. October 1998

1999

95. J. McCormack. **Heart Attack and Strokes: What are the risks and can they be reduced with prescription drugs - Patient Seminar, (2 separate seminars) Abbotsford, Victoria, BC. 1999
96. J. McCormack. *Drug Therapy Decision Making Physician and Pharmacist Seminar, (10 separate seminars) Vancouver, Prince Rupert, Terrace, Kitimat, Hazelton, Smithers, Vernon, Kelowna, Penticton, Prince George, BC. 1999
97. J. McCormack. Cholesterol - Understanding the risks. St. Paul's Hospital Pharmacy Technicians, Vancouver, BC. March 1999
98. J. McCormack. Evidence-based and emotional-based information about the use of oral medications for whiplash associated disorders. World Congress for Health Care, Traffic Safety, Auto Engineering and Insurance Professionals, Vancouver, BC. March 1999
99. J. McCormack. Antibiotic resistance or resisting antibiotics. Drug Therapy Decision Making Annual Course, Vancouver, BC. March 1999
100. J. McCormack. NIDDM - looking at the numbers. Drug Therapy Decision Making Annual Course, Vancouver, BC. March 1999
101. J. McCormack. Co-coordinator - Drug Therapy Decision Making Annual Course. Physician and Pharmacist 2-day drug therapy course, Richmond, BC. April 1999
102. J. McCormack. OTC's - which work and which don't. Annual Course in Drug Therapy, Montreal, QC. May 1999
103. J. McCormack. Harnessing the energy of the placebo without deception. Annual Course in Drug Therapy, Montreal, QC. May 1999
104. J. McCormack. How to tell the patient about benefits and risks of therapy. Annual Course in Drug Therapy, Montreal, QC. May 1999
105. J. McCormack. Does warning patients about side effects produce them? Annual Course in Drug Therapy, Montreal, QC. May 1999
106. J. McCormack. **Healthy Lifestyles Seminar. Full-day Patient Seminar, Barbados. May 1999
107. J. McCormack. *Drug Therapy Decision Making - Physician and Pharmacist Seminar, Barbados. May 1999
108. J. McCormack. Drug Therapy Decision Making. University of Saskatchewan, Saskatoon, SK. August 1999
109. J. McCormack. NIDDM - looking at the numbers. SPH Grand Rounds, Vancouver, BC. September 1999
110. J. McCormack. **Drug Therapy Decision Making. Federal Securities Group, Vancouver, BC. September 1999
111. J. McCormack. HRT for CHD - A debate. Family Practice Residents, SPH, Vancouver, BC. September 1999
112. J. McCormack. Osteoarthritis and drugs: The evidence behind your decisions. Continuing Pharmacy Education, Victoria. November 1999

2000

113. J. McCormack. How many COX do you need? Drug Therapy Decision Making Annual Course, Richmond. March 2000
114. J. McCormack. Co-coordinator - Drug Therapy Decision Making Annual Course. Physician and Pharmacist 2-day drug therapy course, Richmond, BC. March 2000
115. J. McCormack. Explaining the risk and benefits of drug therapy to patients – how to do a better job. Therapeutics Update 2000 – Continuing Medical Education, Saskatoon, SK. March 2000
116. J. McCormack. When new results challenge old beliefs – What you may not know about Type 2 diabetes, hormone replacement, Colace and Celebrex. Therapeutics Update 2000 – Continuing Medical Education, Saskatoon, SK. March 2000
117. J. McCormack. **Healthy Lifestyles Seminar. Full-day Patient Seminar, Barbados. May 2000
118. J. McCormack. *Drug Therapy Decision Making - Physician and Pharmacist Seminar, Barbados. May 2000
119. J. McCormack. *Drug Therapy Decision Making – Physician and Pharmacist Seminar, Vancouver, BC. June 2000
120. J. McCormack. **Drug Therapy Decision Making. United Steel Workers, New Westminster, BC. November 2000
121. J. McCormack. Treatment of COPD: What to do when the evidence doesn't support your beliefs. CSHP – BC Branch Annual General Meeting, Vancouver, BC. November 2000

2001

122. J. McCormack. **Drug Therapy Decision Making. MRC retirement group, Vancouver, BC. January 2001
123. J. McCormack. Community-Pharmacy based evaluation of bupropion effectiveness. CORE /University of Washington Joint Meeting, Vancouver, BC. January 2001
124. J. McCormack. The use of bone density in the diagnosis and treatment of osteoporosis. Family Practice Residents, Vancouver, BC. February 2001
125. J. McCormack. The influences around us: conflicts of interest, literature bias, marketing and other things to think about. Faculty seminar, Vancouver, BC. February 2001
126. J. McCormack. My biases on literature bias. Drug Therapy Decision Making Annual Course, Richmond, BC. May 2001
127. J. McCormack. Co-coordinator - Drug Therapy Decision Making Annual Course - Physician and Pharmacist 2-day drug therapy course, Richmond, BC. May 2001
128. J. McCormack. **Healthy Lifestyles Seminar. Full-day Patient Seminar, Barbados. May 2001
129. J. McCormack. When new results challenge old beliefs. Grand Rounds Queen Elizabeth Hospital, Barbados. May 2001
130. J. McCormack. *Drug Therapy Decision Making. Family Practise Residents, Vancouver, BC. June 2001
131. J. McCormack. Just say KnoW to drugs - What you need to know before you take any prescription, over-the-counter or "natural" drugs. UBC Faculty Women's Club, Vancouver, BC. October 2001
132. J. McCormack. Drug Therapy Decision Making. Nova Scotia Pharmacists Annual General Meeting (5 talks), Halifax, NS. October 2001
133. J. McCormack. *Drug Therapy Decision Making. CME department for Sharp Rees-Stealy (4 talks) , San Diego, CA. November 2001
134. Richmond General Hospital Grand Rounds – COX-2 controversy, Richmond, B.C November 2001.
135. Cochrane Meeting – Marketing EBM, Edmonton, AB. November 2001
136. GF Strong – COX-2 controversy, Vancouver, B.C. December 2001

2002

137. Co-coordinator - Drug Therapy Decision Making Annual Course - Physician and Pharmacist 2-day drug therapy course, Richmond, BC. May 2002
138. Presenting evidence to patients: Why, how and what to tell patients. Canadian Pharmacists Association Annual Meeting. Winnipeg, MN. May 2002
139. Should HRT be deferred until further research is done? Annual Course in Drug Therapy, Montreal, QC. May 2002
140. When New Evidence Challenges Old Beliefs – Let it! Annual Course in Drug Therapy, Montreal, QC. May 2002
141. *Drug Therapy Decision Making Physician and Pharmacist Seminar, Sioux Lookout, ON. October 2002
142. *Drug Therapy Decision Making. CME department for Sharp Rees-Stealy (4 talks), San Diego, CA. November 2002
143. SPH Grand Rounds – NSAIDs, COX-2'S, betablockers/asthma and other beliefs, Vancouver, B.C. November 2002
144. J.McCormack. Thinking outside the box: challenging dogma treatment of COPD - CSHP – BC Branch Annual General Meeting, Vancouver, BC. November 2002

2003

145. PDW Conference. When is a 20% reduction worth it? Halifax NS. January 2003
146. Richmond General Hospital Grand Rounds – The ALLHAT Trial. Richmond, B.C. January 2003
147. Richmond General Hospital Grand Rounds – HRT and bone density – a bone of contention. Richmond, B.C. February 2003
148. Co-coordinator - Drug Therapy Decision Making Annual Course - Physician and Pharmacist 2-day drug therapy course, Richmond, BC. April 2003
149. Evidence based OTC's. Canadian Pharmacists Association Annual Meeting. Vancouver. June 2003
150. Is there strong evidence for primary prophylactic therapy of hyperlipidemia? Annual Course in Drug Therapy, Montreal, QC. May 2003
151. The top 50 - brief "evidence-based" pointers for many of the "top 50" drugs you prescribe. Annual Course in Drug Therapy, Montreal, QC. May 2003
152. Surrey Memorial Hospital Grand Rounds – Healthy Skepticism. Surrey. May 2003
153. Surrey Memorial Hospital Grand Rounds – Healthy Skepticism 2. Surrey. May 2003
154. Is there any reason to do BMD testing? – Debate with David Kendler, Vancouver June, 2003
155. Do statins have a role in primary prevention? Healthy Heart Annual General meeting, Vancouver September, 2003
156. Drug Therapy Decision Making. CME department for Sharp Rees-Stealy (2 talks), San Diego, CA. September 2003
157. Drug Therapy Decision Making Physician and Pharmacist Seminar, Fort St John. September 2003 – full day course
158. Drug Therapy Decision Making Physician and Pharmacist Seminar, Dawson Creek. September 2003 – full day course
159. Drug Therapy Decision Making Physician and Pharmacist Seminar, Peace River. September 2003 – full day course
160. Optimal Prescribing Course. Rural Family Practice Residents, Vancouver, October 2003
161. Continuing Pharmacy Education. Do statins have a role in primary prevention? Victoria, December 2003
162. Internal Medicine Rounds, St Paul's Hospital. Do statins have a role in primary prevention? Vancouver December 2003
163. Family Practice Telerounds, Vancouver, December 2003

2004

164. A day in the mind of ... PDW Annual Conference, Vancouver, January, 2004
165. Richmond General Hospital Grand Rounds – Do statins have a role in primary prevention? Richmond, B.C. January 2004
166. Surrey Memorial Hospital Grand Rounds – The top 50 - brief "evidence-based" pointers for many of the "top 50" drugs you prescribe. Surrey. February 2004
167. Surrey Memorial Hospital Grand Rounds – Do statins have a role in primary prevention? Surrey. February 2004
168. Richmond General Hospital Grand Rounds – Glucose and blood pressure – how sweet it isn't and how low do you go? Richmond, B.C. February 2004
169. Richmond General Hospital Grand Rounds – How to tell patients about risk reduction and side effects. Richmond, B.C. March 2004
170. Richmond General Hospital Grand Rounds – Top 50 drugs. Richmond, April 2004
171. Co-coordinator - Drug Therapy Decision Making Annual Course - Physician and Pharmacist 2-day drug therapy course. Richmond, BC. April 2004
172. St. Paul's Hospital - General Internal Medicine Rounds. Vancouver, April 2004
173. Burnaby General Hospital – Grand Rounds - Do statins have a role in primary prevention?, Burnaby, April 2004
174. Family Medicine Rural Residents Video Conference - Do statins have a role in primary prevention?, Vancouver, April 2004
175. Drug Therapy Decision Making Physician and Pharmacist Seminar. Whitehorse, Yukon, May 2004 – full day course
176. Consumers and drugs – the evidence. Whitehorse, Yukon, May 2004
177. Family Medicine Rural Residents Video Conference – Diabetes – glucose and BP. Vancouver, May 2004
178. UBC Family Practice – EBM Therapeutics. Vancouver, June, 2004
179. Chinese Physician Contingent at UBC – ½ day seminar. Vancouver, August 2004
180. Children's Hospital Emergency Physicians – Evidence Based Health Care. Vancouver, August 2004
181. UBC School of Journalism, Marketing, Media, Drugs. Vancouver, September, 2004
182. Drug Therapy Decision Making. CME department for Sharp Rees-Stealy (6 talks - Statins, COX2s, Topical NSAIDs, Andropause, Antibiotics, Biologics). San Diego, CA. October 2004
183. Canadian Cardiovascular Society Annual Meeting - Do statins have a role in primary prevention? Calgary, October 2004
184. Family practice regimens. Optimal Prescribing Course. UBC, October 2004
185. SPH Family Practice Debate. Do statins have a role in primary prevention? Vancouver, November 2004
186. Atlantic Pharmacists Annual General Meeting. (5 talks – Beliefs, Statins, Decision-making, COPD, Clopidogrel). Halifax, November 2004
187. St Paul's Family Practice Annual Course – The debate around measuring bone mineral density. Vancouver, November 2004
188. Women's Hospital - Principles of prescribing. Vancouver November 2004
189. Burnaby General Hospital – Grand Rounds – COX-2s. Burnaby April 2004

2005

190. Drug Therapy Decision Making Physician and Pharmacist Seminar. Kelowna, January 2005 – full day course
191. Teleconference – Rural Family Practice Residents. Vancouver, January 2005

192. Just say Know to Drugs – Family physicians and pharmacists. Burnaby, January 2005
193. Just say Know to Drugs – Family physicians and pharmacists. Surrey, February 2005
194. Just say Know to Drugs – Family physicians and pharmacists. Chilliwack, February 2005
195. The pitfalls of ethics and studies. Clinical Coordinators. Vancouver, February 2005
196. Co-coordinator - Drug Therapy Decision Making Annual Course - Physician and Pharmacist 2-day drug therapy course. Richmond, BC. April 2005
197. Cholesterol Debate - Great Cardiology Debates, Toronto, May 2005
198. EBM Therapeutics - Nurse practitioners BCIT, May 2005
199. Bone density monitoring – Continuing Pharmacy Education, Internet Conference, June 2005
200. Surrey Memorial Hospital Grand Rounds – NSAIDs, atenolol, ASA? Surrey. June 2005
201. What the TI does – Taipei physicians. Vancouver, July 2005
202. Just say Know to Drugs – Family physicians and pharmacists. Trail/Castlegar/Nelson, September 2005
203. Just say Know to Drugs – Family physicians and pharmacists. Cranbrook, September 2005
204. Drug Therapy Decision Making Physician and Pharmacist Seminar. Victoria, September 2005 – full day course
205. St Paul's Family Practice Annual Course – Is this drug safe? Vancouver, October 2005
206. CSHP- BC branch AGM – Aminoglycoside ototoxicity –why is the evidence still falling on deaf ears? November 2005
207. Surrey Memorial Hospital Grand Rounds – A host of new beliefs, Diabetes, CAP etc Surrey. December 2005

2006

208. Drug Therapy Decision Making Physician and Pharmacist Seminar. Kelowna, January 2006 – full day course
209. St. Paul's Hospital – Family Practice Rounds – Values in guidelines. Vancouver January 2006
210. Richmond General Hospital Grand Rounds – Values in guidelines. Richmond March 2006
211. Co-coordinator - Drug Therapy Decision Making Annual Course - Physician and Pharmacist 2-day drug therapy course. Richmond, BC. April 2006 – 3 talks (Intro, betablockers, diabetes)
212. Interior Health Pharmacy Meeting – ColdFx – is it really a beauty? and Aminoglycoside ototoxicity –why is the evidence still falling on deaf ears? – Kamloops, May 2006
213. Cholesterol Debate - Great Cardiology Debates, Toronto, May 2006
214. Diabetes Guidelines Debate – Vancouver – May 2006
215. Richmond General Hospital Grand Rounds – Evidence vs Guidelines - Richmond, B.C. June 2006
216. Peace River Drug Therapy Course – 2 day course – Sept 2007
217. UBC Emeritus Professors – Just Say Know To Drugs – UBC – September 2006
218. Family practice rounds. Optimal Prescribing Course. UBC- September 2006
219. Richmond General Hospital Grand Rounds – Beta-blockers - Richmond, B.C. October 2006
220. UBC Dept Family Medicine Teleconference – Therapeutic Myths – Vancouver October 2006
221. Pharmacists Prescribing. CAPSI debate – UBC October 2006
222. Just say Know to Drugs – Family physicians and pharmacists – 2 day course Prince George, November 2006
223. UBC/Vancouver Women's Business Club – Just Say Know to Drugs – December 2006

2007

224. Professional Practice Conference – Pharmacists – 2 talks (Media and You, Guidelines and Values) – Toronto – January 2007
225. Drug Therapy Course – Physicians and Pharmacists – Barbados – February 2007
226. Just Say Know to Drugs – Family Practice Residents – Regina – March 2007
227. Drug Therapy Course – Physicians and Pharmacists - Keynote and Breakout session – Regina - March 2007
228. Co-coordinator - Drug Therapy Decision Making Annual Course - Physician and Pharmacist 2-day drug therapy course. Vancouver BC. April 2007 – 3 talks (Intro, Cold-Fx, antipsychotics, cardiology)
229. Annual Evidence-Based Psychopharmacology Richmond Hospital Department of Psychiatry Clinical Day – 2 talks (Intro and antipsychotics 3rd) – April 2007
230. Metabolic Syndrome Debate - Great Cardiology Debates, Toronto, May 2007
231. Youth Health In-service – Teach your children well - encouraging healthy skepticism in you and your patients. Vancouver – June 2007
232. With Tejani A - Hospital Pharmacy Residents – Critical appraisal skills and healthy skepticism – 5 days – Burnaby – August 2007
233. Richmond Grand Rounds – The metabolic syndrome – do we really need another syndrome? – Richmond – October 2007
234. Family physician course. When new information challenges old beliefs, let it! (10 hours) – New York, Halifax, Boston – October 2007
235. New Westminster Family Practice Rounds - The metabolic syndrome – do we really need another syndrome? – New Westminster - October 2007
236. Family practice rounds. Optimal Prescribing Course. UBC – October 2007
237. With Rangno R - UBC Women's Club – OTC drugs and other information you need to know about prescription drugs - Vancouver – November 2007
238. St Paul's Family Practice Course – The “best” statin and NNT's – Vancouver – November 2007
239. Knowledge Translation in the Post Market Evaluation of Drug Safety and Effectiveness Data – Discussant – Ottawa - November 2007
240. BC College of Family Physicians Congress - How to get the most and the least out of "new" drugs – Vancouver – December 2007

2008

241. Vancouver Coastal Clinical Trials Symposium - The risks and benefits of discussing risks and benefits – Vancouver – February 2008
242. Skin Care Research Day - The risks and benefits of discussing risks and benefits– Vancouver - March 2008
243. CSHP Annual Banff Conference - Shooting for Lipid/Blood Pressure/HbA1c Targets: Beware the Collateral Damage - Banff – March 2008

244. Co-coordinator - Drug Therapy Decision Making Annual Course - Physician and Pharmacist 2-day drug therapy course. Vancouver BC. April 2008 – 3 talks (Intro, Framingham, Respiriology Debate)
245. Where is the value in Clinical Practice Guidelines? Plus something to raise your BP - Great Cardiology Debates, Toronto, May 2008
246. With Tejani A - Hospital Pharmacy Residents – Critical appraisal skills and healthy skepticism – 5 days – Burnaby – August 2008
247. Family practice rounds. Optimal Prescribing Course. UBC – August 2008
248. Family Practice Conference – Peace River Medical Association – Rational drug therapy for CVD prevention – Jasper AB - September 2008
249. Research Coordinators Group - The risks and benefits of discussing risks and benefits– Vancouver – September 2008
250. Just Say Know to Drugs – Family Practice Residents – Vancouver – October 2008
251. Annual Yukon Medical Conference – Whitehorse – November 2008

2009

252. Post Graduate Review – Family Practice – Osteoporosis : The Benefits and Harms of Treatment - Making No Bones About It – February 2009
253. Sharp Rees-Stealy Webinar - Measuring CRP - An important part of a Comprehensive Risk Profile or a Completely Ridiculous Practice? – March 2009
254. With Allan M. Institute for Healthcare Improvement - 10th Annual International Summit on Redesigning the Clinical Office Practice, - Fitting patient-centered care into guidelines – Vancouver - March 2009
255. Co-coordinator - Drug Therapy Decision Making Annual Course - Physician and Pharmacist 2-day drug therapy course. Vancouver BC. March 2009 – 2 talks (Back to the Future – 20 years and counting, Light that has emerged from the Black Hole – the Collective experience)
256. CRP – An important part of a Comprehensive Risk Profile or a Completely Ridiculous Practice - Great Cardiology Debates, Toronto, May 2009
257. With Nagge J. Primary health care: Are you really ready? Prato, Italy, May 2009
258. CRP – An important part of a Comprehensive Risk Profile or a Completely Ridiculous Practice – Grand Rounds, Surrey, June 2009
259. LDL, HDL, A1C, SBP, CRP, BMI, BMD and Other Four Letter Words: Let's Put the "Value" Back into Guidelines. CSHP Annual Education Event, Winnipeg, August 2009
260. With Tejani A - Hospital Pharmacy Residents – Critical appraisal skills and healthy skepticism – 5 days – Burnaby – August 2009
261. Open Access and Beyond, UBC, October 2009
262. Just Say Know to Drugs – Family Practice Residents – Vancouver – October 2009
263. With Allan M. - LDL, HDL, A1C, SBP, CRP, BMI, BMD and Other Four Letter Words: Let's Put the "Value" Back into Guidelines. CSHP Edmonton, October 2009
264. LDL, HDL, A1C, SBP, CRP, BMI, BMD and Other Four Letter Words: Let's Put the "Value" Back into Guidelines. Faculty Seminar, UBC, November 2009
265. DNS "Do not substitute" OR "Difference not significant". St Paul's Family Practice Course, Vancouver, November 2009

2010

266. Post Graduate Review – Family Practice – Will Power (lifestyle) vs Pill Power (medication) for Primary Prevention of CVD – February 2010
267. The ABC's of Vitamin D CME-on-the-Run, Vancouver – February 2010
268. With Virani A. Practical Prescribing for Naturopathic Physicians. Vancouver, March - April 2010 – three 2-day courses
269. With Allan M. Introduction and Evidence Review. Drug Therapy Course, Vancouver, April 2010
270. With Allan M. Expert Panel. Drugectomy. Drug Therapy Course, Vancouver, April 2010
271. With Allan M. Evidence Review (CVD, Diabetes, and general practice topics). Regional Conference "Road-show", Trail/Nelson BC, May 2010
272. With Allan M. Cardiovascular risk: evidence review. Family Medicine Residents Annual Conference. Northern Ontario Medical School, Thunder Bay, ON, May 2010
273. With Allan M. Fashion, Trends and Guidelines: The Truth and Art of Evidence. McMaster Family Medicine Rounds. Hamilton, ON, June 2010
274. With Virani A. Practical Prescribing for Naturopathic Physicians. Vancouver, May – June 2010 – three 2-day courses
275. With Allan M. Prescribing in the Elderly: Don't Just Do Something, Stand There. Care of the Elderly. Hamilton, ON, June 2010
276. With Tejani A - Hospital Pharmacy Residents – Critical appraisal skills and healthy skepticism – 5 days – Burnaby – August 2010
277. With Allan M. Incorporating Evidence-Based Practice into Day-to-Day Treatment. Dept of Veterans Affairs CME. Madison, Wisconsin, August 2010
278. With Allan M. Incorporating Evidence-Based Practice into Day-to-Day Treatment. Dept of Veterans Affairs CME. Chicago, Illinois, August 2010.
279. With Allan M. The Risky Business of Prevention: Understanding Baseline Risk and Potential Benefits. GP Registrars Session, Auckland, New Zealand, September 2010
280. With Allan M. Starting to Stop: Tips for Prescribing. Royal New Zealand College of General Practitioners Research Day, Christchurch, New Zealand, September 2010
281. With Allan M. Keynote Address: When the right thing is wrong what's left?" Royal New Zealand College of General Practitioners Conference, Christchurch, New Zealand, September 2010
282. With Virani A. Practical Prescribing for Naturopathic Physicians. Vancouver, October 2010 – 2-day course
283. Ethics Seminar. Things that annoy the clinical research ethics board. Vancouver, October 2010
284. Just Say Know to Drugs – Family Practice Residents – Vancouver – October 2010

285. How to interact with drug interactions. St Paul's Family Practice Course, Vancouver, November 2010

2011

286. With Virani A. Practical Prescribing for Naturopathic Physicians. Vancouver, January 2011
287. Post Graduate Review – Family Practice Drugs work and are safe but what does work and safe mean? Vancouver, February 2011
288. Critical Thinking, Kitsalano High School – Grade 12, Vancouver, March 2011
289. With Allan M, Virani A. Evidence Review (CVD, Diabetes, and general practice topics). Regional Conference “Road-show”, Prince George BC, March 2011
290. With Allan M. Challenging the guidelines workshop. Nurse Practitioners Conference - Medicine Hat - March 2011
291. With Allan M. Won't get fooled again – The WHO, what why, where and when of therapeutics, Target shooting and target dosing – Bullseye or BS DTC course Vancouver - April 2011
292. Medical Myths You Need To Learn About Before It's TOO Late. Regeneration Group – Vancouver - April 2011
293. With Virani A. Practical Prescribing for Naturopathic Physicians. Vancouver - May 2011 – 2-day course
294. Challenging guidelines - Chilliwack Division of Family Practice AGM - Chilliwack - May 2011
295. With Tejani A - Hospital Pharmacy Residents – Critical appraisal skills and healthy skepticism – 5 days – Burnaby – July 2011
296. With Allan M. Starting to Stop: Tips for Prescribing. Royal New Zealand College of General Practitioners Research Day, Christchurch, New Zealand, September 2010
297. With Allan M. Keynote Address - Baffled, befuddled and bemused: how to not get fooled again - Royal New Zealand College of General Practitioners Conference, Auckland, New Zealand, September 2011
298. With Virani A. Practical Prescribing for Naturopathic Physicians. Vancouver, September 2011 – 2-day course
299. With Mike A. Mythbusters of therapeutics: Explore. Collaborate. Innovate GP11 – the Conference for General Practice - Hobart, Australia – Web presentation Oct 2011
300. Family practice residents. Don't get fooled again and again, Osteoporosis : The Benefits and Harms of Treatment - Making No Bones About It, The Risky Business of Prevention: Understanding Baseline Risk and Potential Benefits. Chilliwack, October 2011
301. Don't get fooled again and again. Dentist Group – Vancouver - October 2011
302. Family practice rounds. Optimal Prescribing Course. SPH. October 2011
303. With Allan M. Guidelines, patient values, your values, and other great therapeutic myths. Nurse Practitioner Conference – Fredericton – October 2011
304. With Allan M. Baffled, befuddled and bemused: how to not get fooled again. Dalhousie University Pharmacy and Medical students. Halifax – October 2011
305. With Allan M. Forgotten or Forgettable: Dispelling some of our Medical Myths Diabetes, Guidelines and the Less than Sweet Evidence Around “Too Much Sugar, Patience with Patients – Discussing Evidence Around Risks, Benefits, and Side Effects, Don't just do something, STAND THERE! Prescribing in the Elderly. Fall Pharmacy Refresher – Halifax - October 2011
306. The collateral damage of target doses. St Paul's Family Practice Course, Vancouver - November 2011
307. Medical Myths You Need To Learn About Before It's TOO Late. ProBus – Vancouver - December 2011

2012

308. Baffled, befuddled and bemused: how to not get fooled again. Faculty Seminar – Vancouver, Mar 2012
309. When the right thing is wrong what's left? Zbeetnoff Memorial Drug Therapy Conference - Saskatoon, Mar 2012
310. Assessing risk and making decisions – workshop. Zbeetnoff Memorial Drug Therapy Conference – Saskatoon, Mar 2012
311. Baffled, befuddled and bemused: how to not get fooled again. VIHA Pharmacy Conference – Parksville, Mar 2012
312. With Tejani A. Forgotten or Forgettable: Dispelling some of our Medical Myths. VIHA Pharmacy Conference – Parksville, Mar 2012
313. Baffled, befuddled and bemused: how to not get fooled again. 23rd Annual Pharmacy Alumni Update Conference – Vancouver, Mar 2012
314. The WHO, what, why, where and when of therapeutics – top 10 things you can count on. DTC course Vancouver - April 2012
315. How to critically appraise an RCT in 10 minutes. DTC course Vancouver - April 2012
316. Dissemination - and Beyond - The Art of Podcasting. CADTH symposium Ottawa – April 2012
317. Baffled, befuddled and bemused: how to not get fooled again. Family Practice Rounds. Coquitlam – April 2012
318. Baffled, befuddled and bemused: how to not get fooled again. Family Practice Conference. London, Ontario – May 2012
319. How to critically appraise an RCT in 10 minutes. Family Practice Conference. London, Ontario – May 2012
320. With Allan M. Family Baffled, befuddled and bemused: how to not get fooled again. Nurse Practitioner Conference. Medicine Hat - June 2012
321. With Allan M. Getting Practical about Practice Guidelines - shining Evidence on Guidelines & Performance Measures. Nurse Practitioner Conference. Medicine Hat - June 2012
322. Baffled, befuddled and bemused: how to not get fooled again. Family Practice Rounds. Chilliwack – June 2012
323. Baffled, befuddled and bemused: how to not get fooled again. APhA annual meeting. Calgary – September 2012
324. How well does it really work – the good the bad and the ugly. Practical Evidence for Informed Practice Course. Edmonton – October 2012
325. Why repeating bone mineral densities and lipid levels leads to repeated confusion. Practical Evidence for Informed Practice Course. Edmonton – October 2012
326. Ontario prescribing and therapeutics certification course for Naturopathic Doctors – 4 day course. Toronto – November 2012
327. Refluxing the evidence so you can potentially prescribe ideally (PPI). St Paul's Family Practice Course. Vancouver - November 2012
328. COPD evidence - How to make meaning out of mean data. CSHP Annual Conference. Vancouver – November 2012
329. Disinfecting some infectious disease myths. VIHA clinical rounds. Victoria – December 2012
330. Don't get fooled again and again. Dentist Group – Vancouver – December 2012
331. Supplemental evidence on supplements. CME on the Run – Vancouver – December 2012

2013

332. With Virani A. Practical Prescribing for Naturopathic Physicians. Vancouver, January 2013 – 2-day course

333. Prescribing a Drugectomy – Who, Why, What, When, Where, and How. Professional Practice Conference. Toronto - February 2013
334. Medical Myths You Need To Learn About Before It's TOO Late. Open Heart Society Consumer Group, Vancouver - February 2013
335. CME on the Run – Family Practice - Top 10 Useless Meds in the Elderly. Vancouver - February 2013
336. Post Graduate Review – Family Practice - The Top Useless Meds in the Elderly. Vancouver - March 2013
337. Baffled, befuddled and bemused: how to not get fooled again. APhA annual meeting. Edmonton - March 2013
338. Medical Myths You Need To Learn About Before It's TOO Late. ProBus Women. North Vancouver - March 2013
339. Medical Myths You Need To Learn About Before It's TOO Late. Consumer group. White Rock - April 2013
340. With Allan M. A Sixth Sense – how to make numbers less frightening. DTC course Vancouver - April 2013
341. With Allan M. Apocalyptic revelations around risk assessment. DTC course Vancouver - April 2013
342. Why regularly repeating BMD, LDL, and SBP is BAD medicine. DTC course Vancouver - April 2013
343. Medical Myths You Need To Learn About Before It's TOO Late. ProBus Men. North Vancouver - May 2013
344. AFPC Award Presentation. Niagra-on-the Lake – June 2013
345. With Allan M. Baffled, befuddled and bemused: how to not get fooled again. Australian Medical Students Association Annual Meeting. Gold Coast, Australia – July 2013
346. Debate – alcohol and its effects on society. Australian Medical Students Association Annual Meeting. Gold Coast, Australia – July 2013
347. Baffled, befuddled and bemused: how to not get fooled again. Bond University. Gold Coast, Australia – July 2013
348. Baffled, befuddled and bemused: how to not get fooled again. Rosalind Franklin University College of Pharmacy, North Chicago – September 2013
349. Baffled, befuddled and bemused: how to not get fooled again. VA Hines, Chicago - September 2013
350. Alberta prescribing and therapeutics certification course for Naturopathic Doctors – 4-day course. Calgary– September 2012
351. Generic drugs DNS - do not substitute or difference not significant. Practical Evidence for Informed Practice Course. Edmonton – October 2013
352. Infectious disease myths. Practical Evidence for Informed Practice Course. Edmonton – October 2013
353. Family practice rounds. Optimal Prescribing Course. UBC – October 2013
354. Baffled, befuddled and bemused: how to not get fooled again. Dental Education Group. Gibsons – October 2013
355. Baffled, befuddled and bemused: how to not get fooled again. Science 101 UBC – November 2013
356. Baffled, befuddled and bemused: how to not get fooled again. Hospital Faculty Development - 1st at Joint Base Lewis McChord, Tacoma, WA – November 2013
357. How to critically appraise an RCT in 10 minutes. Hospital Faculty Development - 1st at Joint Base Lewis McChord, Tacoma, WA – November 2013
358. Medical Myths You Need To Learn About Before It's TOO Late. Living to 120 conference. Vancouver – November 2013
359. Baffled, befuddled and bemused: how to not get fooled again. Dental Education Group. Vancouver – November 2013

2014

360. Baffled, befuddled and bemused: how to not get fooled again. PDW conference. Vancouver – January 2014
361. Panel Discussion – job opportunities. PDW conference. Vancouver – January 2014
362. Tom Hanks and Type 2 Diabetes – an evidence-based discussion I would like to have with Mr Hanks. Faculty Seminar UBC, Vancouver – January 2014
363. Medical Myths You Need To Learn About Before It's TOO Late. Hollyburn Country Club. West Vancouver – January 2014
364. Prescribing a Drugectomy – Who, Why, What, When, Where, and How. Optimizing Medications Workshop. Vancouver - January 2014
365. Tom Hanks and Type 2 Diabetes – an evidence-based discussion I would like to have with Mr Hanks. Center for Clinical Epidemiology Rounds, Vancouver – January 2014
366. Vitamin D or Vitamin D'oh. Faculty Alumni Conference, Vancouver – March 2014
367. Prescribing a Drugectomy – Who, Why, What, When, Where, and How. CSHP Conference. Banff - March 2014
368. With Allan M. Numbers – silver tongue/forked tongue. DTC course Vancouver - April 2014
369. CVD risk reduction – the one with the most birthdays wins. DTC course Vancouver - April 2014
370. Baffled, befuddled and bemused: how to not get fooled again. Dental Education Group. Richmond – April 2014
371. How to critically appraise an RCT in 10 minutes. APA Evidence-Based Pediatrics SIG meeting. Vancouver – April 2014
372. Less is more, more or less. Fraser Valley Family Physicians. Coquitlam – April 2014
373. Baffled, befuddled and bemused: how to not get fooled again. Dental Education Group. Vancouver – May 2014
374. Baffled, befuddled and bemused: how to not get fooled again. How to critically appraise an RCT in 10 minutes. Tom Hanks and Type 2 Diabetes – an evidence-based discussion I would like to have with Mr Hanks. Dental Education Group. Kamloops – May 2014
375. Less is more, more or less. CVD risk reduction – the one with the most birthday's wins, Osteoporosis – making no bones about it. Infectious disease myths, Supplemental evidence on supplements. Family Physicians. Salmon Arm – May 2014
376. Less is more, more or less. How to critically appraise an RCT in 10 minutes. UBC Psychiatry residents. Vancouver – May 2014
377. Tom Hanks and Type 2 Diabetes – an evidence-based discussion I would like to have with Mr Hanks. Alumni weekend. UBC – May 2014
378. Medical Myths You Need To Learn About Before It's TOO Late. Capilano Country Club. West Vancouver – May 2014
379. Baffled, befuddled and bemused: how to not get fooled again. Tom Hanks and Type 2 Diabetes – an evidence-based discussion I would like to have with Mr Hanks. Nurse Practitioners Annual Conference. Victoria - May 2014
380. Risk Assessment Tools in Chronic Disease. UBC Rural Rounds – webinar. Vancouver – August 2014
381. Nutrition and the Evidence Conundrum. Faculty Seminar, UBC - September, 2014
382. Baffled, befuddled and bemused: how to not get fooled again. Tom Hanks and Type 2 Diabetes – an evidence-based discussion I would like to have with Mr Hanks. Nutrition and the Evidence Conundrum. Dental Hygienists – Pacific Rhapsody Conference. Burnaby – September 2014
383. The ongoing failure of three letter surrogate markers (A1c, SBP, LDL) and what if anything does the CREB need to do about it. Annual CREB educational program. UBC – October 2014

384. Nutrition and the Evidence Conundrum. Faculty of Law Seminar, University of Alberta - October, 2014
 385. Diet, Food, and Health: You Aren't "What You Eat" But You Are "How Much You Eat". Hard Fracts on Brittle Bones: Diagnosing, Treating (and Untreating) Osteoporosis. Practical Evidence for Informed Practice Course. Edmonton – October 2014
 386. Supplemental evidence on supplements. BCCFP 2014 Fall Family Medicine Conference. Vancouver – October 2014

2015

387. Baffled, befuddled and bemused: how to not get fooled again. Food and You – Nutrition and the evidence conundrum. Cosmos Dental Group. Vancouver - January 2015

10. SERVICE TO THE UNIVERSITY

(a) Memberships on committees, including offices held and dates

Faculty of Pharmaceutical Sciences Committees (member unless otherwise indicated)

Technology Working Group – co-chair - 2012
 Faculty Executive committee, 2010-2012
 Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences. Member 1986 –1995, Chair/Co-Chair 1995 – 2009
 Doctor of Pharmacy Development Program, Faculty of Pharmaceutical Sciences. 1986 - 1991
 Pharm. D. Task Force Committee, Faculty of Pharmaceutical Sciences. 1991 - present
 Pharm. D. Selection Committee, Faculty of Pharmaceutical Sciences. 1991 - present
 Task Force on Recruitment and Admissions, Faculty of Pharmaceutical Sciences. Chair 1994-1995
 Promotion Committee, Faculty of Pharmaceutical Sciences. 1995 - 2000
 Appeals Committee, Faculty of Pharmaceutical Sciences. 1995 - 2000
 Merit Committee, Faculty of Pharmaceutical Sciences. 1995 - 2008
 Faculty Council, Faculty of Pharmaceutical Sciences. 1999 - 2012
 Dawson Fund Committee and subcommittee, Faculty of Pharmaceutical Sciences. 1999 - 2000
 New Curriculum Committee, Faculty of Pharmaceutical Sciences. 1999 - 2005
 PCDM working group (New Curriculum), Faculty of Pharmaceutical Sciences. 2000
 Clinical working group (New Curriculum), Faculty of Pharmaceutical Sciences. 2000
 Faculty Representative, Hospital Residency Program, UBC. 2001 – 2012

Other University Committees (member unless otherwise indicated)

Executive Committee, Therapeutics Initiative, UBC. 1994 - 2009
 Scientific Information and Education Committee of the Therapeutics Initiative, UBC. 1994 - 2009
 Education Committee, Therapeutic Initiative, UBC. 1994 - 2009
 J.F. McCreary Lecture Committee, Office of the Coordinator of Health Sciences, UBC. Member 1987 – 1995, Chair from 1995 –1998
 Interprofessional Activities Health and Human Service Programs, Office of the Coordinator of Health Sciences, UBC. Chair from 1999 – 2007
 College of Health Disciplines, Office of the Coordinator of Health Sciences, UBC. 2001 – 2007
 Associate Chair, Clinical Research Ethics Board, UBC. 2002-2012
 Chair, UBC Protocol Review Committee, 2003-2005
 Chair, St. Paul's Protocol Review Committee, 2003 – 2005

(b) Other service, including dates

Judy Soon Ph.D. exam committee – 2000
 Arun Verma M.Sc. exam committee – 2001

11. SERVICE TO THE COMMUNITY

(a) Memberships on scholarly societies, including offices held and dates

Member, British Columbia College of Pharmacists. 1982 – present
 Member, Canadian Society of Hospital Pharmacists. 1983 – 1997
 Member, American Society of Hospital Pharmacists. 1986 - 88
 Rho Chi Society. 1986 - present
 Member, American College of Clinical Pharmacy. 1986 - 88
 Member, American Association of Pharmaceutical Sciences. 1991-1992
 Member, Canadian Society of Clinical Pharmacology. 1992 – 2002
 Member, BC Pharmacists Association. 2014

(b) Memberships on other societies, including offices held and dates

(c) Memberships on scholarly committees, including offices held and dates

(d) Memberships on other committees, including offices held and dates

Antibiotic Subcommittee, St. Paul's Hospital. 1986 - 89
 Pharmacy and Therapeutic Committee, St. Paul's Hospital. 1986-89
 Advisory board for Drug Advisory Committee, College of Pharmacists. 1991-1993
 Coordinator, Drug Usage Evaluation program, St. Paul's Hospital. 1986-89
 Coordinator, Hospital Pharmacy Residency Program, St. Paul's Hospital. 1986-88

(e) Editorships (list journal and dates)

Editorial Advisory Board for Focus:Infectious Disease Canada 1988 – 1991

(f) Reviewer (journal, agency, etc. including dates)

Professional Advisory Board, Revised Edition of Understanding Canadian prescription drugs, Dorothy Smith, Editor 1990
 On Call:Principles and Protocols, Gillies JH, Marshall SA, Ruedy J. W.B. Saunders. 1991
 Review panel for CPHA (CPS and Therapeutic Choices) 1993-2005
 Reviewer, The Clinical Journal of Pain. Editor, Peter Wilson. 1993-94
 Abstracts for Canadian Pharmacoepidemiology Meeting. 1995
 Annals of Pharmacotherapy. 1995
 American Journal of Medicine. 1995
 European Journal of Clinical Microbiology. 1995
 Therapeutics Letter Reviewer. 1994
 Canadian Journal of Clinical Pharmacology. 1995
 Cochrane Collaborative – Consumers and Communication. 2001
 British Medical Journal
 Canadian Family Physician
 Canadian Journal of Hospital Pharmacy
 Canadian Journal of Clinical Pharmacology
 JAMA Internal Medicine

(g) External examiner (indicate universities and dates)**(h) Consultant (indicate organization and dates)**

Patented Medicine Prices Review Board – Human Drug Advisory Panel member 2002-2008
 American Federal Trade Commission - Therapeutic and Clinical Trials Expert 2008-present
 Expert Witness on many medical negligence cases 1995- present

12. AWARDS AND DISTINCTIONS**(a) Awards for Teaching (indicate name of award, awarding organizations, date)**

The Eric Elder Medal – Royal New Zealand General Practitioners - 2011
 UBC Pharm D Program's Instructor Award – 2012
 AFPC National Award for Excellence in Education – 2013

(b) Awards for Scholarship (indicate name of award, award organizations, date)

Rho Chi Society (Pharmacy Honor Society) 1986
 PMAC/MRC Research Fellowship - two years - Sept 1989 - 91

13. PUBLICATIONS/SCHOLARLY ACTIVITY

- A. When listed as first author, I conceived and planned the work that led to the paper or interpreted the evidence it presents. I also wrote the first draft, and submitted the final draft.**
- B. When listed as second or other author, I reviewed successive versions and took part in the revision process and approved the final version.**
- C. Publications considered of primary importance are indicated with an asterisk (*)**

(a) Refereed Articles

1. Pleasants RA, Gadsden RH, McCormack JP, Pivalar KM, Sawyer, WT. Interference of digoxin like immunoreactive substances with three digoxin immunoassays in patients with various degrees of renal function. *Clin Pharm* 1986; 5:810-816.
2. McCormack JP, Schentag JJ. Potential impact of quantitative susceptibility tests on the design of aminoglycoside dosing regimens. *Drug Intell Clin Pharm* 1987; 21:187-192.
3. McCormack JP. Comment: Impact of a kinetic service on aminoglycoside patients. *Drug Intell Clin Pharm* 1989;23:622 (Letter)
4. Levine M, McCormack JP. Comment: Unusual digoxin concentrations. *Drug Intell Clin Pharm* 1989;23:717-8 (Letter)
5. McCormack JP, Levine M, Miller P. Bioequivalence: Just the facts please. *Can Pharm J* 1990;9:404-7
6. McCormack JP, Pleasants RP, O'Neal W. The accuracy of vancomycin delivery with retrograde administration at low flow rates. *Hosp Pharm.* 1990; 25:933-6
7. McCormack JP, Reid SE, Lawson LM. Theophylline toxicity induced by tetracycline. *Clin Pharm* 1990;9:546-9
8. *McCormack JP, Jewesson PJ. A critical reevaluation of the therapeutic range of aminoglycosides. *Clin Inf Dis(formerly Rev Inf Dis)*. 1992;14:320-39
9. Wong C, Warriner B, McCormack JP, Clarke AM. Reconstituted thiopentone retains its alkalinity without bacterial contamination for up to four weeks. *Can J Anaesth.* 1992;39:504-8
10. McCormack JP, Warriner B, Levine M et al. Regularly dosed oral morphine for post surgical orthopedic pain. *Can J Hosp Phar* 1992;45:101-5.
11. McCormack JP, Brown GR. Disagreement with liability for failure to monitor serum gentamicin concentrations. *Am J Hosp Pharm* 1992;49:2928-9 (Letter)
12. Brown G, Miyata M, McCormack JP. Drug concentration monitoring; An approach to rational use. *Clin Pharmacokinet* 1993;24:187-94
13. McCormack JP, Stratton T, Rangno R. Read with Caution. *Ann Pharmacother* 1993;27:794-5 (Letter)
14. McCormack JP. Aminoglycoside/Vancomycin nephrotoxicity. *Can J Hosp Pharm* 1993;46:145
15. *McCormack JP, Warriner CB, Levine M, Glick N. A comparison of regularly dosed oral morphine and on-demand intramuscular morphine in the treatment of postsurgical pain. *Can J Anaesth* 1993;40:819-24
16. Angel JB, Hussey EK, Hall ST, Donn KH, Morris DM, McCormack JP, Montaner JS, Ruedy J. Pharmacokinetics of 3TC (GR109714X) administered with or without food to HIV-infected patients. *Drug Invest* 1993;6:70-7
17. McCormack JP, Levine M. Meaningful interpretation of risk reduction from clinical drug trials. *Ann Pharmacother* 1993; 27:1272-7
18. McCormack JP, Li R, Singer J, Zarowny D. Inadequate treatment of pain in ambulatory HIV patients. *Clin J Pain* 1993; 9:279-83
19. Brown G, McCormack JP. Letter to the Editor. *Int Care Med* 1994;20:243 (Letter)

20. *McCormack JP, Rangno RE. An evaluation and critique of the use of lipid-lowering drugs in a population base of 400,000 patients over the age of 65. *Can J Clin Pharmacol* 1994;1(1):27-32
21. McCormack JP, Rangno RE. Cholesterol lowering in the elderly *Can J Clin Pharmacol* 1994;1(2):51-2 (Letter)
22. McCormack JP, Rangno RE. Cholesterol lowering in the elderly *Can J Clin Pharmacol* 1994;1(3):99-100 (Letter)
23. Montgomery CJ, McCormack JP, Reichert C, Marsland C. Plasma concentrations after high- dose (45mg/kg) rectal acetaminophen in children. *Can J Anaesth* 1995;42:982-6
24. McCormack JP, Rangno RE. Dose Titration: Minimize to Maximize. *Therapeutics Letter* (www.ti.ubc.ca). October 1995;10:1-2
25. McCormack JP, Rangno RE, Wright J. Evidence Based Drug Therapy: What Do the Numbers Mean? *Therapeutics Letter* (www.ti.ubc.ca). August/September/October 1996;15:1-4
26. *McCormack JP, Levine M, Rangno RE. Primary prevention of heart disease and stroke: a simplified approach to estimating risk of events and making drug treatment decisions. *Can Med Assoc J* 1997;157:422-8
27. McCormack JP, Cooper, J, Carleton B. Simple approach to dosage adjustment in patients with renal disease. *Amer J Health Syst Pharm* 1997;54:2505-9
28. Bass F, McCormack JP. Effective clinical tobacco intervention. *Therapeutics Letter*. (www.ti.ubc.ca). September - October 1997;21:1-4
29. McCormack JP, Carleton B. A simpler approach to pharmacokinetic dosage adjustments. *Pharmacotherapy* 1997;17:1349-51
30. McCormack JP, Loewen P. Treatment of acute migraine headaches. *Therapeutics Letter*. (www.ti.ubc.ca). November-December 1997;22:1-4
31. McCormack JP, Levine M, Rangno RE. Patients offered treatment for CHD need full information to make decision. *BMJ* 1998; 316: 1021-2 (Letter)
32. *Maclure M, Dormuth C, Naumann T, McCormack J, Rangno R, Whiteside C, Wright JM. Influences of educational interventions and adverse news about calcium channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia. *Lancet* 1998; 352: 943-48
33. McCormack JP, Bassett K. The evidence for insulin lispro. *Can Med Assoc J*. 1998;159:1353 (Letter)
34. *McCormack JP, Levine M, Rangno RE. An easier approach to estimating risk of coronary heart disease and stroke. *Circulation* 1999;99:2219 (Letter)
35. McCormack JP, Bassett K. The evidence for insulin lispro. Letter to the Editor. *Can Med Assoc J*. 1999;160:1551 (Letter)
36. McCormack JP, Bassett K. Celecoxib (Celebrex[®]) Is it a Breakthrough Drug? *Therapeutics Letter*. (www.ti.ubc.ca) August-September 1999;31:1-2
37. Scheepers LD, Montgomery CJ, Kinahan AM, Dunn GS, Bourne RA, McCormack JP Plasma concentration of flumazenil following intranasal administration in children. *Can J Anaesth*. 2000;47(2):120-4
38. *McCormack JP, Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. *BMJ* 2000;320:1720-3
39. McCormack JP, Greenhalgh T. Seeing what you want to see in randomised controlled trials – Author’s reply. *BMJ* 2000;321:1078 (Letter)
40. *McCormack JP. An emotional-based medicine approach to monitoring once-daily aminoglycosides. *Pharmacotherapy*. 2000;20:1524-7
41. McCormack JP, Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. *WJM* 2001; 174:123-127 (a slightly adapted version of above BMJ article)

42. McCormack JP, Jewesson P. The influences around us: be wary of writers' biases. *J Inform Pharmacother* 2001;4:1-3 (Invited editorial)
43. McCormack JP, Levine M. Dual blockade of renin-angiotensin system – data do not support claimed benefit of combination over single treatment. *BMJ* 2001;322:1183 (Letter)
44. McCormack JP. Absolute vs. relative numbers in evaluating drug therapy. *Amer Fam Physician*, 2001;63:1913 (Letter)
45. McCormack JP. Generic vs. brand name drugs: The warfarin debate is wearing thin. *J Inform Pharmacother* 2001: 6 (Invited editorial)
46. McGrath AM, Gardner DM, McCormack J. Is home peak expiratory flow monitoring effective for controlling asthma symptoms? *J Clin Pharm Ther* 2001; 26:311-317
47. Nair K, Dolovich L, Cassels A, McCormack JP, Levine M, Gray J, Mann K, Burns S. What patients want to know about their medications. Focus group study of patient and clinician perspectives. *Can Fam Physician* 2002;48:104-10
48. McCormack J, Perry T, Rangno R, van Breemen C, Wright JM Assessing the quality of clinical practice guidelines *Can Med Assoc J* 2002;166:168 (letter)
49. McCormack JP, Rangno RE Digging for data from the cox-2 trials. *Can Med Assoc J*;166:1649-50, 2002
50. McCormack JP. ALLHAT – so what. *J Informed Pharmacotherapy* 2003;12:1
51. *Cassels A, Hughes MA, Cole C, Mintzes B, Lexchin J, McCormack JP. Drugs in the news: How well do Canadian Newspapers report the good, the bad and the ugly of new drugs. *Can Med Assoc J* 2003;168:1133-7
52. *McCormack JP, Dolovich L, Levine M, Burns S, Nair K, Cassels A, Mann K, Gray J. Providing evidence-based information to patients in general practice and pharmacies: What is the acceptability, usefulness and impact on drug use? *Health Expectations* 2003;6:281-9
53. McCormack J, Loewen P, Jewesson P. Why is There No Value in Clinical Practice Guidelines? *J Informed Pharmacotherapy* 2003;14
54. McCormack J, Loewen P, Jewesson P. Dissemination of results needs to be tracked as well as the funding is. (letter) *BMJ* 2005;331:456
55. McCormack JP, Johns K, Tildesley H. Metformin's contraindications be contraindicated? *CMAJ* 2005;173:503-4
56. McCormack J, Loewen P. The other side of the bezafibrate infarction prevention trial data.[Comment. Letter] *Arch Intern Med*. 2005;165:2431-2
57. *Dolovich L, Burns S, Cassels A, Levine M, Nair K, McCormack JP, Mann K, Gray J. Using patient-oriented evidence-based information guides in practice: The family physician and community pharmacist perspective. *Drug Information Journal*. 2006;40:61-67
58. Elan C, Paluck EC, McCormack JP, Ensom MHH, Levine M, Soon JA, Fielding DW. Outcomes of bupropion therapy for smoking cessation during routine clinical use. *Ann Pharmacother* 2006;40: 185-90
59. *McCormack JP, Loewen P. Adding “value” to clinical practice guidelines. *Can Fam Physician* 2007;53:1327-35
60. McCormack JP. Do β -blockers have a role in treating hypertension?: NO *Can Fam Physician* 2007;53:614-7
61. Wright J, McCormack JP. Mild Hypertension - An approach to using evidence in the decision making process. *Therapeutics Letter*. (www.ti.ubc.ca) 2007;62:1-2
62. McCormack JP, Wright J. Using Framingham for primary prevention cardiovascular risk assessment. *Therapeutics Letter*. (www.ti.ubc.ca) 2007 63:1-2
63. McCormack JP. Number needed to treat and baseline risks. *CMAJ* 2008;179:1174
64. Dersch D, McCormack JP Estimating Renal Function for Drug Dosing: Rewriting the Gospel? *CJHP* 2008;61:138-43

65. *McCormack JP, Allan GM. Measuring hsCRP - An important part of a Comprehensive Risk Profile or a Completely Redundant Practice? *PLOS Medicine* 2010;7: e1000196. doi:10.1371/journal.pmed.1000196
66. McCormack JP. Should IV Antibiotics Be Administered by Prolonged Infusion? The Con Side. *Can J Hosp Pharm* 2010;63: 248-9
67. Allan GM, Ivers N, McCormack J. Type 2 diabetes and ASA. *Can Fam Physician*. 2010; 56(7):664.
68. *McCormack JP, Allan GM, Virani AS. Is Bigger Better? An argument for “very” low initial doses. *CMAJ* 2010 Oct 4 [Epub ahead of print].
69. McCormack JP. Point/Counterpoint. Should all elderly women receive bisphosphonates to prevent osteoporotic fractures? NO. *CJHP* 2012;65:47-8
70. Korownyk C, Allan GM, McCormack J. Bioidentical hormone micronized progesterone. *Can Fam Physician* 2012;58:755
71. *McCormack JP, Allan GM. A prescription for improved antibiotic prescribing in primary care. *BMJ* 2012;344:d7955
72. Arroll B, Allan GM, Elley CR, Kenealy T, McCormack J, Hudson B, Hoare K Diagnosis in primary care: probabilistic reasoning. *J Prim Health Care* 2012;4:166-73.
73. Korownyk C, Allan GM, McCormack J. Response - Bioidentical hormone therapy. *Can Fam Physician* 2012;58:1334
74. McCormack JP. No evidence base for monitoring aminoglycoside levels. *BMJ* 2012;345:e7264
75. *Allan GM, Nouri F, Korownyk C, Kolber MR, Vandermeer B, McCormack J. Agreement among cardiovascular risk calculators. *Circulation* 2013;127:1948-56
76. McCormack J, Vandermeer B, Allan GM. How confidence intervals become confusion intervals. *BMC Med Res Methodol*. 2013 Oct 31;13:134. doi: 10.1186/1471-2288-13-134
77. Allan GM, Nouri F, Korownyk C, Kolber MR, Vandermeer B, McCormack J. Response to letters regarding "agreement among cardiovascular disease risk calculators". *Circulation* 2013;128 :e430. doi: 10.1161/CIRCULATIONAHA.113.005511
78. McCormack J, Banh HL, Allan GM. Refining the American guidelines for prevention of cardiovascular disease. *Lancet* 2014;9917:598-9
79. Lindblad AJ, Garrison S, McCormack J. Testing vitamin D levels. *Can Fam Phys* 2014;60:351
80. Allan GM, Garrison S, McCormack J. Comparison of cardiovascular disease risk calculators. *Curr Opin Lipidol* 2014;25:254-65
81. Martin SA, McCormack JP, Newman DH. Letter - Changes in Diabetes-Related Complications in the United States. *N Engl J Med* 2014;371:284
82. McCormack JP. Blood Pressure Medicines for Five Years to Prevent Death, Heart Attacks, and Strokes. *thennt.com* 2014 <http://www.thennt.com/nnt/anti-hypertensives-to-prevent-death-heart-attacks-and-strokes/>
83. McCormack JP, Chmelicek JT. Generic versus brand name: the other drug war. *Can Fam Phys* October 2014 60: 911
84. Korownyk C, Kolber MR, McCormack J, Lam V, Overbo K, Cotton C, Finley C, Turgeon RD, Garrison S, Lindblad AJ, Banh HL, Campbell-Scherer D, Vandermeer B, Allan GM. Televised medical talk shows-what they recommend and the evidence to support their recommendations: a prospective observational study. *BMJ* 2014 Dec 17;349:g7346. doi: 10.1136/bmj.g7346.
85. Caulfield T, Clark MI, McCormack JP, Rachul C, Field CJ. Representations of the health value of vitamin D supplementation in newspapers: media content analysis. *BMJ Open* 2014;4:e006395 doi:10.1136/bmjopen-2014-006395

(b) Conference Proceedings

1. McCormack JP, Warriner B, Levine M et al. The use of regularly dosed oral morphine in the treatment of pain following total hip arthroplasty. *Can J Anaesth* 1990;37:S57
2. Wong C, Warriner B, McCormack JP. The incidence of contaminated pentothal vials following routine use. *Anesthesiology* 1990;73(suppl 3A):A1030
3. Warriner B, McCormack JP, Levine M et al. A double blind comparison of intermittent intramuscular morphine and regularly scheduled oral morphine in the treatment of postsurgical pain. *Can J Anaesth* 1992 (suppl):A72
4. Ruedy J, Angel J, McCormack JP. Pharmacokinetics of GR109714X (3TC) in HIV infected patients when administered with and without food. VIII International Conference on AIDS, Amsterdam 19024 July 1992:PoB 3008
5. McCormack JP, Li R, Singer J, Zarowny D. Incidence of pain in ambulatory HIV patients. VIII International Conference on AIDS, Amsterdam 19024 July 1992:PoB 3551
6. McCormack JP, Rangno RE. The use of lipid-lowering agents in a population base of 400,000 patients over the age of 65. *Clin Invest Med* 1993;16:102
7. Montgomery CJ, McCormack JP, Reichert C, Marsland C. Plasma concentrations following high dose (45mg/kg) rectal acetaminophen in pediatrics. Society for Pediatric Anesthesia and Academy of Pediatrics Section on Anesthesiology. 1995:42
8. Nair K, Dolovich L, Levine M, Gray J, Mann K, McCormack JP, Cassels A. Patient and clinician perception of patient medication information needs. *Clin Pharmacol Ther* 2000; 67:140
9. Gray J, Cassels A, Levine M, McCormack JP, Mann K, Dolovich L. Providing evidence-based information to patients: impact on physician prescribing. ASCPT Annual Meeting, Orlando 2001
10. Dolovich L, Levine M, Gray J, Mann K, McCormack J, Cassels A, Nair K, Burns S. Patient perception of evidence-based therapeutic information guides. ASCPT Annual Meeting Orlando 2001
11. McCormack JP, Dormuth C, Rangno R. Presentation of evidence-based information about the UKPDS to small groups of general practitioners changes the prescribing of oral hypoglycemics to type 2 diabetic patients. Canadian Cochrane Symposium 2001
12. Godolphin W, Towle A, McCormack JP, Rangno R, McKendry R. What do patients do with evidence based information? A randomised controlled trial. Shared Decision Making Conference, Oxford, UK, 2001
13. Soon JA, Ensom MHH, Fielding DW, Levine M, McCormack JP, Santi SM. Involvement of a community pharmacist research network in evaluating outcomes of bisphosphonate therapy. *J Pharm Pharmaceut Sci* 2004;7:299-300
14. Soon JA, Ensom MHH, Fielding DW, Levine M, McCormack JP, Metge C. Pharmacist-Based Surveillance of Drug Effectiveness and Safety. 2004 Health Canada
15. Metge C, Soon J, MacKinnon N, Moride Y, Fielding D, Levine M, McCormack J, Ensom M, LeLorier J, Sketris I. An Evaluation Framework for "Therapeutic Effectiveness" 2004. Health Canada Science Forum.
16. Soon JA, Ensom MHH, Fielding DW, Levine M, McCormack JP, Santi SM. Involvement of a community pharmacist research network in evaluating outcomes of bisphosphonate therapy. *J Pharm Pharmaceut Sci* 2004;7:299-300
17. Soon JA, Ensom MHH, Fielding DW, Levine M, McCormack JP, Metge C. Pharmacist-Based Surveillance of Drug Effectiveness and Safety. 2004 Health Canada Science Forum
18. Metge C, Soon J, MacKinnon N, Moride Y, Fielding D, Levine M, McCormack J, Ensom M, LeLorier J, Sketris I. An Evaluation Framework for "Therapeutic Effectiveness" 2004. Health Canada Science Forum
19. Soon JA, Ensom MHH, Fielding DW, Levine M, McCormack JP, Metge CJ Linkage of Field Study Data from the Community Pharmacist Research Network with Medical Office Records 2006 CHSPR meeting
20. Kwok P, Low A, McCormack J, Nicholl T – The Pharmaceutical Care Clinic AFPC/CPERC – Richmond - June 2010
21. Mok S, Low A, McCormack J, Nicholl T – The Pharmacists Clinic AFPC/CPERC – Winnipeg - June 2011

22. Korownyk C, Kolber MR, McCormack J, V Lam, Overbo K, Finley C, Lindblad A, Bahn HL, Garrison S, Turgeon R, Campbell-Scherer D, Cotton C, Vandermeer B, Allan GM. Medical Information (Reliability & Accuracy) in Popular Television. Annual Scientific Assembly, Banff, Alberta, Alberta College of Family Physicians, Feb 27, 2014
23. Wilcock J, McCormack J. Bohemian Polypharmacy. Annual Primary Care Conference. Royal College of General Practitioners. Liverpool, England. October 2, 2014

(c) Non-refereed Journals

1. McCormack JP. The selection of antibiotics for the treatment of otitis media. BC Pharmacist 1991;5:8-9
2. McCormack JP. Decreasing or stopping antihypertensives may be as important as treating hypertension. BC Pharmacist 1991;6:13,22
3. McCormack JP. The "Cholesterol Quest" - Prescribing lipid-lowering medications to the over-sixty five patient. BC Pharmacy 1992;1(1):14,16.
4. McCormack JP. Sustained release NSAIDS and their role in the treatment of arthritic conditions. BC Pharmacy 1992;2:11-2
5. McCormack JP, Chang A. The use of non-prescription products in patients with diabetes. Reach 1992;3:10-12,27
6. McCormack JP. Dose titration: the key to successful drug use? BC Pharmacy 1992;1(3):6-7
7. McCormack JP. The patients best interest: The pharmacist's commitment. BC Pharmacy 1993;1(4):7,22-3
8. McCormack JP. Ulcer treatments may prove new therapies are not always the best. BC Pharmacy 1993;2(1):20,23
9. McCormack JP. Judging the results: Take care when interpreting prevention trial studies: much of it is relative. BC Pharmacy 1993;2(2):18-9
10. McCormack JP. Book review of "Pathology and Therapeutics for Pharmacists" Can Pharm J 1993;392
11. McCormack JP. Who knows more about drugs - Physicians or pharmacists? BC Pharmacy 1993;2(3):19-20
12. McCormack JP. Optimizing therapy. Patient diversity calls for dose individualization. BC Pharmacy 1994;3(1):24-5
13. McCormack JP. The new wonder drugs - check the data first. BC Pharmacy 1994;3(3):21-22
14. McCormack JP. NSAIDs and the elderly: considerations for appropriate use. BC Pharmacy 1994;3(4):19-20
15. McCormack JP, Boothroyd J. Drug ad hard to swallow. AdBusters. 1998;22:18-9
16. McCormack JP. Evidence-based and emotional-based information about the use of oral medications for whiplash associated disorders. Recovery. 1999

(d) Books - Edited

1. *Editor: Gray J. Associate Editors: Cusson J, Gillis A, Johnson G, MacLeod S, McCormack J, McLean W, Patterson C, Rangno R, Reider M. Therapeutic Choices. Canadian Pharmaceutical Association 1995 (782 pages)
2. *Editor: McCormack JP. Associate Editors: Brown G, Rangno R, Levine M, Ruedy J. Drug Therapy Decision Making Guide. Philadelphia: WB Saunders 1996 (550 pages)
3. *Editor: Gray J. Associate Editors: Cusson J, Gillis A, Johnson G, Johnson J, MacLeod S, McCormack J, McLean W, Patterson C, Rangno R, Reider M. Therapeutic Choices - 2nd edition. Canadian Pharmaceutical Association 1998 (886 pages)
4. Editor: Gray J. Associate Editors: Gillis A, Johnson G, Johnson J, MacLeod S, McCormack J, McLean W, Patterson C, Rangno R, Reider M. Therapeutic Choices – 3rd edition. Canadian Pharmaceutical Association 2000 (978 pages)

5. Editor: Gray J. Associate Editors: Gillis A, Johnson G, Johnson J, MacLeod S, Matsui D, McCormack J, Patterson C, Rangno R, Richardson J. Therapeutic Choices – 4th edition. Canadian Pharmaceutical Association 2003 (1267 pages)

(e) Book Chapters

1. McCormack JP, Brown G. Traumatic skin and soft tissue infections. In: Young et al., eds. Applied Therapeutics. Vancouver WA: Applied Therapeutics – 6th edition; 1995:66-1-66-10
2. McCormack JP, Carleton B. Dosage Adjustment in Renal Failure. In: Gray et al., eds. Therapeutic Choices. Canadian Pharmaceutical Association; 1995:727-38
3. Rangno R, McCormack JP. Drug therapy for hypertension. In: McCormack JP et al., eds. Drug Therapy Decision Making Guide. Philadelphia:WB Saunders;1996:3-9
4. McCormack JP, Brown G. Drug therapy for reflux esophagitis. In: McCormack JP et al., eds. Drug Therapy Decision Making Guide. Philadelphia:WB Saunders;1996:50-1
5. McCormack JP, Brown G. Drug therapy for peptic ulcer disease and stress ulcers. In: McCormack JP et al., eds. Drug Therapy Decision Making Guide. Philadelphia:WB Saunders;1996:51-6
6. McCormack JP. Drug therapy for pneumonia. In: McCormack JP et al., eds. Drug Therapy Decision Making Guide. Philadelphia:WB Saunders;1996:74-7
7. McCormack JP. Drug therapy for meningitis. In: McCormack JP et al., eds. Drug Therapy Decision Making Guide. Philadelphia:WB Saunders;1996:83-5
8. Allaire C, McCormack JP. Drug therapy for sexually transmitted disease. In: McCormack JP et al., eds. Drug Therapy Decision Making Guide. Philadelphia:WB Saunders;1996:85-90
9. MacDougall C, McCormack JP. Drug therapy for soft tissue infections. In: McCormack JP et al., eds. Drug Therapy Decision Making Guide. Philadelphia:WB Saunders;1996:91-4
10. MacDougall C, McCormack JP. Drug therapy for osteomyelitis. In: McCormack JP et al., eds. Drug Therapy Decision Making Guide. Philadelphia:WB Saunders;1996:94-6
11. McCormack JP, Carleton B, Cooper J. Dosage Adjustment in Renal Failure. In: Gray et al., eds. Therapeutic Choices – 2nd edition. Canadian Pharmaceutical Association; 1998:824-37
12. McCormack JP, Carleton B, Cooper J. Dosage Adjustment in Renal Failure. In: Gray et al., eds. Therapeutic Choices – 3rd edition. Canadian Pharmaceutical Association; 2000:901-15
13. McCormack JP, Brown G. Rational Use of Drug Concentration Measurements. In: Murphy, ed. Clinical Pharmacokinetics Pocket Reference. American Society of Health-System Pharmacists, Bethesda 2000.
14. McCormack JP, Brown G. Traumatic skin and soft tissue infections. In: Young et al., eds. Applied Therapeutics – 7th edition; Lippincott Williams &Wilkins; 2001:65-1-65-12
15. McCormack JP, Carleton B, Cooper J. Dosage Adjustment in Renal Failure. In: Gray et al., eds. Therapeutic Choices – 4th edition: Canadian Pharmaceutical Association 2003;1189-214
16. McCormack JP, Brown G. Rational Use of Drug Concentration Measurements. In: Murphy, ed. Clinical Pharmacokinetics Pocket Reference. – 3rd edition: American Society of Health-System Pharmacists
17. McCormack JP, Brown G. Traumatic skin and soft tissue infections. In: Young et al., eds. Applied Therapeutics – 8th edition; Lippincott Williams &Wilkins 2003
18. McCormack JP, Carleton B, Cooper J. Dosage Adjustment in Renal Failure. In: Gray et al., eds. Therapeutic Choices – 5th edition: Canadian Pharmaceutical Association 2007
19. McCormack JP. Rational Use of Drug Concentration Measurements. In: Murphy, ed. Clinical Pharmacokinetics Pocket Reference. – 4th edition: American Society of Health-System Pharmacists. 2008
20. McCormack JP, Brown G. Traumatic skin and soft tissue infections. In: Young et al., eds. Applied Therapeutics – 9th edition; Lippincott Williams &Wilkins 2008

21. McCormack JP, Brown G. Traumatic skin and soft tissue infections. In: Young et al., eds. Applied Therapeutics – 10th edition; Lippincott Williams & Wilkins 2011
22. McCormack JP. Rational Use of Drug Concentration Measurements. In: Murphy, ed. Clinical Pharmacokinetics Pocket Reference. – 5th edition: American Society of Health-System Pharmacists. 2011
23. McCormack JP, Carleton B, Cooper J. Dosage Adjustment in Renal Failure. In: Therapeutic Choices – 6th edition: Canadian Pharmaceutical Association. 2011

(f) Other

Therapeutics Education Collaboration Podcasts – with Mike Allan – see therapeuticseducation.org

WEEKLY EPISODES**2008**

1. Episode 1: Philosophy, guidelines and the truth
2. Episode 2: Evidence does not equal decision-making
3. Episode 3: The risky business of CVD risk assessment
4. Episode 4: De-constructing Risk (or Benefit)
5. Episode 5: Swiss Cheese and The Evidence Holes in the Lipid Hypothesis
6. Episode 6: Hypertension: Coping with the Pressure
7. Episode 7: Hypertension: Taking the Pressure Off (Stage 1)
8. Episode 8: Taking the Pressure Off: Hypertension Drugs
9. Episode 9: News Flash: Aggressive Blood Sugar Control Not All Sweet
10. Episode 10: Taking the Pressure Off: ACE Inhibitors
11. Episode 11: Taking the Pressure off: Other Drugs
12. Episode 12: Getting Hyper Tense about Monitoring
13. Episode 13: Bun-Out: Silencing The Smoking Gun* in Health
14. Episode 14: Listener Mail: Addressing the Questions and Confusion
15. Episode 15: Treating Depression: The Recent Sad News about Anti-Depressants
16. Episode 16: Anti-Depressants: Is there a Drug of Choice?
17. Episode 17: Anti-Depressants: Some Issues in Managing Depression
18. Episode 18: Osteoporosis: The Initial Approach to Bone-Density
19. Episode 19: Osteoporosis: Treating for Fracture Reduction
20. Episode 20: Mysteries within Enigmas: Answering Listener Mail
21. Episode 21: The Down-Low on Low Dose: The Logic
22. Episode 22: The Down-Low on Low Dose: The How-To
23. Episode 23: De-Bugging the Approach to Pneumonia
24. Episode 24: De-Bugging the Approaches to Ear Infections and Strep Throat
25. Episode 25: De-Bugging the Approaches to Sinusitis and Bronchitis
26. Episode 26: Confusing Overwhelming Puffer Data leaving us Breathless
27. Episode 27: COPD: Breathing Life into Effective (and some not) COPD Treatments
28. Episode 28: Creating Confusion or Clarity: Q and A of Listener Mail
29. Episode 29: Creating Confusion or Clarity- Q and A of Listener Mail - 2
30. Episode 30: A New Far-out Trial: Welcome to Jupiter
31. Episode 31: Old Ideas for Coping with New Drugs
32. Episode 32: Aches and Pains: An Overview of Osteoarthritis Treatment
33. Episode 33: NSAIDS. Considering the Risks and Benefits
34. Episode 34: Holiday Extravaganza: Confirming or dispelling myths and beliefs?
35. Episode 35: Information on older drugs from an even older doctor

2009

36. Episode 36: Information on older drugs from an even older doctor - Part 2
37. Episode 37: Diverse listener questions and comments - Q & A with unfortunately no answers
38. Episode 38: New trials you need to know about
39. Episode 39: New trials you need to know about- Part 2
40. Episode 40: Keeping up with the medical literature - 101
41. Episode 41: Obesity - what's the big deal?
42. Episode 42: Obesity - what's the big dot? - Part II
43. Episode 43: Obesity - what's the big deal? - Part III
44. Episode 44: Practice Changing Articles - with Double the Mikes
45. Episode 45: Practice Changing Articles - with Double the Mikes Part II
46. Episode 46: High quality information on drug safety - Special Guest Dr. Bruce Psaty
47. Episode 47: The April Fools'/Happy 1st Anniversary Podcast
48. Episode 48: Becoming less anxious about anxiety disorders
49. Episode 49: Becoming less anxious about anxiety disorders – Part II
50. Episode 50: More useful clinical trials – with a gentler touch
51. Episode 51: More useful clinical trials – with a gentler touch – Part II
52. Episode 52: CRP – An important part of a Comprehensive Risk Profile or a Completely Ridiculous Practice
53. Episode 53: CRP – An important part of a Comprehensive Risk Profile or a Completely Ridiculous Practice- Part II
54. Episode 54: CRP – An important part of a Comprehensive Risk Profile or a Completely Ridiculous Practice- Part III
55. Episode 55: Type 2 Diabetes – how sweet it isn't

56. Episode 56: Type 2 Diabetes – how sweet it isn't – Part II
57. Episode 57: Type 2 Diabetes – how sweet it isn't – Part III
58. Episode 58: Type 2 Diabetes – how sweet it isn't – Part IV
59. Episode 59: Type 2 Diabetes – how sweet it isn't – Part V
60. Episode 60: Type 2 Diabetes – how sweet it isn't – Part VI
61. Episode 61: Type 2 Diabetes – how sweet it isn't – Part VII
62. Episode 62: Type 2 Diabetes – how sweet it isn't – THE END
63. Episode 63: More listener questions with answers leaving more questions
64. Episode 64: More listener questions with answers leaving more questions – Part II
65. Episode 65: A clot, a clot, I want it not – primary prevention with antiplatelets
66. Episode 66: A clot, a clot, I want it not – secondary prevention with antiplatelets
67. Episode 67: A clot, a clot, I want it not – secondary stroke prevention with antiplatelets
68. Episode 68: The “heart of the matter” for stroke prevention in atrial fibrillation
69. Episode 69: More studies you need to know about
70. Episode 70: More studies you need to know about – Part II
71. Episode 71: PBS, PSA and YOU – a plea, a pledge and a prostate

2010

72. Episode 72: WE'RE BACK with Vitamin D, vim, and vigor
73. Episode 73: Vitamin D – dose, diet and dermatologists – Part II
74. Episode 74: Vitamin A, B, C, NOT D, and E – not all letters are created equal
75. Episode 75: Starting insulin and stopping pain or is it stopping insulin and starting pain?
76. Episode 76: The frail elderly – “philosophy first” – Part I
77. Episode 77: The frail elderly – blood pressure is good – Part II
78. Episode 78: The frail elderly – treat symptoms first, last and in the middle – Part III
79. Episode 79: Listener comments and questions with an attempt at answers
80. Episode 80: Listener comments and questions with an attempt at answers – Part II
81. Episode 81: New studies
82. Episode 82: Lost faith in surrogates yet? ACCORD challenges beliefs again
83. Episode 83: Gabapentin and bioidentical hormones – a look at ALL the data
84. Episode 84: Alzheimer's – unforgettable podcasts – part I – the diagnosis
85. Episode 85: Alzheimer's – unforgettable podcasts – part II – the scales and the studies
86. Episode 86: Alzheimer's – unforgettable podcasts – part III – the final tease
87. Drugectomies – DTC 2010
88. Episode 87: Increasing the likelihood you will use likelihood ratios?
89. Episode 88: A hodgepodge from down under – smoking, ASA, antibiotics, NSAIDs, warfarin, spironolactone
90. Episode 89: Warts and all – part three of the New Zealand experience
91. Episode 90: Zoster pain and the pain of using PPIs with clopidogrel
92. Episode 91: A potpourri of osteoporosis stuff
93. Episode 92: Bupropion for sex and surgery for MS
94. Episode 93: Questions posed, answers (de)composed – N and V, statins, ASA and Alzheimer's
95. Episode 94: More questions posed, and more answers composed – Benzos, serotonin syndrome, big pressures and low doses
96. Episode 95: Making the treatment of low back pain less of a pain in the derrière – part 1
97. Episode 96: Making the treatment of low back pain less of a pain in the derrière – part 2
98. Episode 97: New stuff that we found – MMR/autism, metformin, A1c and colchicine
99. Episode 98: Inhaled steroids, LABAs and much much more – breathing life into the evidence
100. New Zealand – shake, rattle and roll
101. Episode 100: Thanks for listening
102. Episode 101: Target doses for CHF - is there collateral damage when shooting for targets?
103. Episode 102: Blood pressure targets: Bullseye or Bulls--t
104. Episode 103: Are there side effects from telling patients about side effects?
105. Episode 104: A high dose of acute asthma therapeutics
106. Episode 105: A higher dose of chronic asthma therapeutics
107. Episode 106: Treating depression with the ultimate low-dose interventions
108. Episode 107: A rash of therapies for common and uncommon skin conditions
109. Episode 108: Questions, questions and more questions
110. Episode 109: More, questions, questions and more questions
111. Episode 110: Even more, questions, questions and more questions

2011

112. Episode 111: PREMIUM – New stuff you really need to know about
113. Episode 112: Dabigatran versus Warfarin, James versus Mike, Right versus Wrong
114. Episode 113: How to interact with drug interactions
115. Episode 114: Topical information on topical NSAIDs

116. Episode 115: PREMIUM - Honey, should you shoot the NSAIDs?
117. Episode 116: New media about otitis media treatment
118. Episode 117: The mind boggles and the heart goes all a flutter
119. Episode 118: The mind boggles and the heart goes all a flutter - Part 2
120. Episode 119: The mind boggles and the heart goes all a flutter - Part 3
121. Episode 120: PREMIUM - Two interesting studies for your patients with coughs and colds
122. Episode 121: An atraumatic way to break down the evidence around bone density measurements
123. Episode 122: The evolution of an evidence-based doctor
124. Episode 123: Eat what you want as long as it comes from the Mediterranean
125. Episode 124: PREMIUM - Two pulmonary studies with useful results and yet again more data on calcium
126. Episode 125: Questions from near and far and answers from way out
127. Episode 126: Questions from near and far and answers from way out - Part II
128. Episode 127: Questions from near and far and answers from way out - Part III
129. Episode 128: Questions from near and far and answers from way out - Part IV
130. Episode 129: PREMIUM - New studies on old and new diuretics
131. Episode 130: Getting exorcised about the evidence around exercise
132. Episode 131: Multimorbidity: a challenge for EBM and Mike and James
133. Episode 132: Antipsychotics - schizophrenia the condition - part 1
134. Episode 133: Antipsychotics - schizophrenia the drugs - part 2
135. Episode 134: Antipsychotics - schizophrenia the drugs - part 3
136. Episode 135: Antipsychotics - use in the elderly - part 4
137. Episode 136: PREMIUM - A head-to-head comparison of ezetimibe and prunes
138. Episode 137: Putting the patient back into the diabetes guidelines - the VA perspective
139. Episode 138: Seeing right through the evidence for the risk of CT scans
140. Episode 139: PREMIUM - Irritating information about IBS and Cold-FX
141. Episode 140: Polypharmacy - a pollyanna approach to a polymorphic problem
142. Episode 141: Polypharmacy - a pollyanna approach to a polymorphic problem - Part II
143. Episode 142: Polypharmacy - a pollyanna approach to a polymorphic problem - Part III
144. Episode 143: A heads-up look at the prevention of headaches
145. Episode 144: A heads-up look at the prevention of headaches - Part II
146. Episode 145: Don't get fooled again and again - New Zealand September 2011
147. Episode 146: PREMIUM Two potentially practice changing studies
148. Episode 147: Definitely vague questions with vaguely definitive answers
149. Episode 148: Definitely vague questions with vaguely definitive answers - PART II
150. Episode 149: Definitely vague questions with vaguely definitive answers - PART III
151. Episode 150: Respecting frailty in a cognitive way

2012

152. Episode 151: PREMIUM Aiming high and long with two studies that should impact practice
153. Episode 152: Leaking out the evidence around overactive bladders and urge incontinence
154. Episode 153: Roflumilast when you add it on for COPD does it add up?
155. Episode 154: Using antibiotics - how to stop being damned if you do, damned if you don't
156. Episode 155: Antipsychotics for depression - is the news depressing?
157. Episode 156: PREMIUM Injecting common sense into painful problems
158. Episode 157: A dysfunctional discussion about functional dyspepsia and H pylori eradication
159. Episode 158: You say chlorthalidone I say hydrochlorothiazide
160. Episode SPECIAL: Getting the skinny on a number of skin disorders
161. Episode SPECIAL #2: Insomnia treatments you don't need to lose sleep over
162. Episode 159: Critical appraisal by and for dummies – PART I
163. Episode 160: Critical appraisal by and for dummies – PART II
164. Episode 161: Critical appraisal by and for dummies – PART III
165. Episode 162: How to analyse a meta-analysis and at the end not need analysis
166. Episode 163: How to analyse a meta-analysis and at the end not need analysis – PART II
167. Episode 164: PREMIUM Stuff you really need to know about HDL, ASA and metformin
168. Episode 165: Diagnosing type 2 diabetes – as much magic as science
169. Episode 166: The highs and lows of statin dosing
170. Episode 167: An uncommonly good podcast about the common cold
171. Episode 168: Crystallizing the evidence for treating and preventing gout
172. Episode 169: Answering questions then questioning the answers
173. Episode 170: Answering questions then questioning the answers - PART II
174. Episode 171: Answering questions then questioning the answers - PART III
175. Episode 172: A sporting look at sports injuries and their treatments
176. Episode 173: A sporting look at sports injuries and their treatments - PART II
177. Episode 174: PREMIUM Is salt the spice of life and sitting on the fence about PSA screening
178. Episode 175: PREMIUM Pyelonephritis and type 2-diabetes – keep changing your previously held beliefs

179. Episode 176: Hormonal contraception – does it give birth to thromboembolic complications?
180. Episode 177: The evidence around the health benefits of coffee and organic foods
181. Episode 178: Amoxicillin for everything that ails you and your patients
182. Episode 179: Smoking out the evidence around screening for lung cancer
183. Episode 180: A RELYable ARISTOTELian look at ROCKET science
184. Episode 181: Two new and improved drugs that unfortunately aren't
185. Episode 182: The herpes zoster vaccine, the numbers, the decisions
186. Episode 183: Proton-pump inhibitors - the evidence for the good and the bad
187. Episode 184: PREMIUM - Two more blood pressure/cholesterol changing drugs that are a flop
188. Episode 185: A spine-tingling look at neuropathic pain
189. Episode 186: A spine-tingling look at neuropathic pain – PART II
190. Episode 187: A spine-tingling look at neuropathic pain – PART III
191. Episode 188: PREMIUM – Taking a bite out of fasting for cholesterol measurements and more bad news about low A1cs

2013

192. Episode 189: A New Year brings new questions and some new but mainly old answers
193. Episode 190: A New Year brings new questions and some new but mainly old answers – PART II
194. Episode 191: A New Year brings new questions and some new but mainly old answers – PART III
195. Episode 192: PREMIUM – New essential data on warfarin dosing, inhaled steroids, and exercise
196. Episode 193: Ironing out the evidence for iron supplementation in non-anemic fatigued women
197. Episode 194: The evidence for Vitamin D and folic acid for depression is not all that depressing
198. SPECIAL Episode – Bad Science, Bad Pharma, Good Podcast with Ben Goldacre
199. Episode 195: PREMIUM – The Mediterranean cuisine cruises to another win
200. Episode 196: To drink or not drink cranberry juice for urinary tract infections
201. Episode 197: ADHD – paying attention to the evidence
202. Episode 198: ADHD – paying attention to the evidence – PART II
203. Episode 199: ADHD – paying attention to the evidence – PART III
204. Episode 200: Please stop measuring all those cholesterol levels
205. Episode 201: Please stop measuring all those cholesterol levels – Part II
206. Episode 202: Please stop measuring all those bone densities
207. Episode 203: PREMIUM – Vitamin D, chelation therapy, and obesity studies you need to know about
208. Episode 204: Please stop measuring all those A1c levels
209. Episode 205: Please stop measuring all those A1c levels – PART II
210. Episode 206: Please stop measuring all those blood pressures
211. Episode 207: Please stop measuring all those blood pressures – PART II
212. Episode 208: PREMIUM – COPD, gout and NSAIDs oh my
213. Episode SUPERLATIVE : A minimally disruptive podcast with Victor Montori
214. Episode 209: A joint look at viscosupplementation for knee osteoarthritis
215. Episode 210: An explosive look at probiotics for the prevention of C.difficile associated diarrhea
216. Episode 211: We told you so, eight times over
217. Episode 212: Questions that lead to questions and then more questions
218. Episode 213: Questions that lead to questions and then more questions - Part II
219. Episode 214: PREMIUM – two more diabetes treatments that fail us yet again
220. Episode 215: Questions that lead to questions and then more questions - Part III
221. Episode 216: Questions that lead to questions and then more questions - Part IV
222. Episode 217: Shining a bright light on the Vitamin D evidence
223. Episode 218: Shining a bright light on the Vitamin D evidence – Part II
224. Episode 219: Shining a bright light on the Vitamin D evidence – Part III
225. Episode 220: Confusing confidence intervals
226. Episode 221: Finally getting the cholesterol guidelines right – almost
227. Episode 222: Do we have any treatments for osteoporotic vertebral fracture pain?
228. Episode 223: PREMIUM – What pioglitazone, fever, bone density and tennis elbow have in common
229. Episode 224: Generically speaking
230. Episode 225: Vaccines - how many pricks do you really need?

2014

231. Episode 226: Vaccines - how many pricks do you really need? Part II
232. Episode 227: Vaccines - how many pricks do you really need? Part III
233. Episode 228: PREMIUM – The new JNC8 high blood pressure guidelines dissected and exposed
234. Episode 229: Prevention and Treatment of the Common Cold - making sense of the evidence
235. Episode 230: Prevention and Treatment of the Common Cold - making sense of the evidence – Part II
236. Episode 231: Prevention and Treatment of the Common Cold - making sense of the evidence – Part III
237. Episode 232: A passing podcast for the failing heart
238. Episode 233: A passing podcast for the failing heart – Part II

239. Episode 234: PREMIUM – Fatty acids and should you eat acetaminophen during pregnancy
240. Episode 235: Antiplatelets - is a one and a two winnerful, winnerful?
241. Episode 236: We listen and respond to listener questions
242. Episode 237: We listen and respond to listener questions – PART II
243. Episode 238: PREMIUM – two new cardiovascular studies and a bit about cough
244. Episode 239: Erecting the evidence around testosterone replacement in men
245. Episode 240: The futility of trying to hit all those guideline targets
246. Episode 241: Industry and us
247. Episode 242: Industry and us - PART II
248. Episode 243: Industry and us - PART III
249. Episode 244: Industry and us - PART IV
250. Episode 245: Three studies you need to know about – so get a PREMIUM membership!
251. Episode 246: Clearing up the confusion around statin-induced cognitive impairment
252. Episode 247: How the new anticoagulants compare to warfarin in DVTs and PEs
253. Episode 248: The effect of NSAIDs on fracture healing – much ado about nothing?
254. Episode 249: Is glucosamine inert or does it help if you are inert from osteoarthritis?
255. Episode 250: New Studies – two podcasts for the price of one
256. Episode 251: PREMIUM – a new heart failure study and much, much more
257. Episode 252: Food and You – the evidence conundrum
258. Episode 253: Food and You – the evidence conundrum – PART II
259. Episode 254: Food and You – the evidence conundrum – PART III
260. Episode 255: We can measure lipoproteins but is there really any point?
261. Episode 256: How much of CVD is in your genes?
262. Episode 257: PREMIUM - Coenzyme Q10, antibiotics and alopecia areata
263. Episode 258: IMPROVE-IT – ezetimibe, what it does and doesn't do
264. Episode 259: The periodic health exam gets examined
265. Episode 260: The periodic health exam gets examined – PART II
266. Episode 261: The periodic health exam gets examined – PART III
267. Episode 262: Televised medical talk shows – the recommendations and the evidence ALSO HOSTED ON THE BMJ site

Other podcasts

1. British Sports Medicine Journal Podcast – November 2013
“Mythbuster” on NSAIDs in sports medicine, challenging nutrition dogma, and evidence-based practice
2. Vancouver Sun Podcast – March 2014
The Health Food Delusion with John Sloan and Randy Shore
3. Questioning Medicine Podcast - November 2014
Holy Grail of Diabetes Discussion

Internet publications

1. Levine M, McCormack JP. The scoop on clinical trials. Medbroadcast Website
http://www.medbroadcast.com/clinical_trials/clinical_trials_help.asp 2000
2. Levine M, McCormack JP. Hormone replacement therapy and heart disease: why use hormone replacement therapy? Medbroadcast Website
http://www.medbroadcast.com/health_topics/sexual_health/index.shtml?hormone_replace_therapy.html 2000
3. McCormack JP, Gray J, Cassels A, Levine M, Mann K, Dolovich L. So you want to learn more about treating Osteoporosis ..what should you know? Canada Drug Guide Website
<http://www.canadadrugguide.org/osteoporosis.html> 2000
4. McCormack JP, Gray J, Cassels A, Levine M, Mann K, Dolovich L. So you get heartburn ..now what do you do? Canada Drug Guide Website <http://www.canadadrugguide.org/heartburn.html> 2000
5. McCormack JP, Gray J, Cassels A, Levine M, Mann K, Dolovich L. So you have a sore throat ..now what do you do? Canada Drug Guide Website <http://www.canadadrugguide.org/throat.html> 2000
6. McCormack JP. Evidence Based Snapshots - Irbesartan and Amlodipine in Patients with Nephropathy due to Type 2 Diabetes. J Informed Pharmacotherapy 2002;9

7. McCormack JP. Evidence Based Snapshots - Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin or Chlorthalidone - The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Informed Pharmacotherapy* 2002;9
8. McCormack JP. Evidence Based Snapshots - Effect of an ACE-inhibitor, Ramipril, on Death from Cardiovascular Causes, MI and Stroke in High Risk Patients (HOPE trial). *J Informed Pharmacotherapy* 2002;9
9. McCormack JP. Evidence Based Snapshots - Losartan versus Atenolol for Hypertension (LIFE): Overall Results and Diabetic Patient Subset. *J Informed Pharmacotherapy* 2002;10
10. McCormack JP. Evidence Based Snapshots - Symptom-Triggered vs. Fixed-Schedule Doses of Benzodiazepine for Alcohol Withdrawal. *J Informed Pharmacotherapy* 2002;10
11. McCormack JP. Evidence Based Snapshots - The Effect of a Proton Pump Inhibitor on the Development of Ulcer Complication Recurrences in Patients taking 100 mg ASA daily. *J Informed Pharmacotherapy* 2002;10
12. McCormack JP. Evidence Based Snapshots - Risks and Benefits of Estrogen plus Progestin in Healthy Postmenopausal Women (Women's Health Initiative). *J Informed Pharmacotherapy* 2002;10
13. McCormack JP. Evidence Based Snapshots - Heart Protection Study - Use of Simvastatin in "High Risk" Individuals. *J Informed Pharmacotherapy* 2002;10
14. McCormack JP. Evidence Based Snapshots - Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients with Septic Shock. *J Informed Pharmacotherapy* 2002;11
15. McCormack JP. Evidence Based Snapshots - Ginkgo for Memory Enhancement. *J Informed Pharmacotherapy* 2002;11
16. McCormack JP. Evidence Based Snapshots - Warfarin, Aspirin, or Both After Myocardial Infarction . *J Informed Pharmacotherapy* 2002;11
17. McCormack JP. Evidence Based Snapshots - Major Outcomes in High-risk Hypertensive Patients Randomized to ACE Inhibitor or Calcium Channel Blocker vs. Diuretic. *J Informed Pharmacotherapy* 2003;12
18. McCormack JP. Evidence Based Snapshots - Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin versus Usual Care. *J Informed Pharmacotherapy* 2003;12
19. McCormack JP. Evidence Based Snapshots - Celecoxib versus Diclofenac and Omeprazole in reducing the risk of Recurrent Ulcer Bleeding in Patients with Arthritis. *J Informed Pharmacotherapy* 2003;12
20. McCormack JP. Evidence Based Snapshots - Does Vitamin D Supplementation reduce Fractures in Men and Women Living in the Community? *J Informed Pharmacotherapy* 2003;13
21. McCormack JP. Evidence Based Snapshots - What Effect does Atorvastatin produce in Hypertensive Patients who have Average or Lower-than-average Cholesterol Concentrations? Results of the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA) . *J Informed Pharmacotherapy* 2003;13
22. McCormack JP. Evidence Based Snapshots Combining - Salmeterol and Fluticasone in the Treatment of Chronic Obstructive Pulmonary Disease: Does it Make a Difference? *J Informed Pharmacotherapy* 2003;13
23. McCormack JP. Evidence Based Snapshots - Comparison of Carvedilol and Metoprolol on Clinical Outcomes in Patients with Chronic Heart Failure in the Carvedilol or Metoprolol European Trial (COMET) Randomized Controlled Trial. *J Informed Pharmacotherapy* 2003;14
24. McCormack JP. Evidence Based Snapshots - Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis. *J Informed Pharmacotherapy* 2003;14
25. McCormack JP. Evidence Based Snapshots - Clinical Efficacy of Three Common Treatments in Acute Otitis Externa in Primary Care: Randomised Controlled Trial. *J Informed Pharmacotherapy* 2004;15
26. McCormack JP. Evidence Based Snapshots - Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both? *J Informed Pharmacotherapy* 200;15
27. McCormack JP. Evidence Based Snapshots - Azithromycin for the Secondary Prevention of Coronary Heart Disease Events: The WIZARD Study. *J Informed Pharmacotherapy* 2004;15

28. Allan GM, McCormack J. Type II diabetics and ASA: Always or Maybe Sometimes? Should ASA be recommended in all patients with Type II diabetes but no history of cardiovascular disease (CVD)? [Publication on the Internet] Tools for Practice, Alberta College of Family Physicians 2009 September 25
29. Allan GM, McCormack J. Long-acting beta-agonist inhalers in asthma: Breathing Evidence into the debate. [Publication on the Internet] Tools for Practice, Alberta College of Family Physicians 2009 December 14.
30. Kolber MR, McCormack J. COLD FX evidence: consistently reported inconsistently. [Publication on the Internet] Tools for Practice, Alberta College of Family Physicians 2011 December 13
31. Korownyk T, McCormack J. Bioidentical Hormone Replacement. [Publication on the Internet] Tools for Practice, Alberta College of Family Physicians 2012 April 5
32. Allan GM, McCormack J. Best Puffer for Initial Therapy in COPD [Publication on the Internet] Tools for Practice, Alberta College of Family Physicians 2012 April 30
33. Korownyk T, McCormack J. Cutting out Sodium in Heart Failure – A Taste of the Evidence. [Publication on the Internet] Tools for Practice, Alberta College of Family Physicians 2013 April 2
34. Lindblad A, Garrison S, McCormack J. Vitamin D Levels: Vitamin Do or Vitamin Don't. [Publication on the Internet] Tools for Practice, Alberta College of Family Physicians 2014 February 3

Major News Outlet Editorials – Huffington Post, Vancouver Sun, Toronto Star, Winnipeg Free Press, Medical Post, canada.com

1. Getting the right dose – July 2012
<http://umanitoba.ca/outreach/evidencenetwork/archives/6487>
2. Medical podcasts cover wide range of topics - with heaping dose of humour – October 2012
<http://www.vancouversun.com/technology/all/Medical+podcasts+cover+wide+range+topics+with+heaping+dose/7465652/story.html>
3. Why heart health is not just a numbers game – June 2013
<http://umanitoba.ca/outreach/evidencenetwork/archives/5663>
4. New cholesterol treatment guidelines reassess statin drug use – December 2013
<http://umanitoba.ca/outreach/evidencenetwork/archives/16192>
5. Surefire tricks to get the most out of your vitamin supplements – February 2014
6. Digesting the evidence - Just how many servings of fruits and vegetables should we eat a day? – August 2014

YouTube Videos

1. Drug Too – July 2012
<http://youtu.be/OlfOW8candA>
2. The Surrogate Battle – is lower always better – January 2013
<http://youtu.be/XCv0CTNRa3I>
3. Some Studies That I Like To Quote – March 2013
<http://youtu.be/lj8bPX8IINg>
4. Viva La Evidence - August 2013
<http://youtu.be/QUW0Q8tXVUc>
5. Make It Easy – September 2013
<http://youtu.be/b18EWaTevu4>
6. Doctor (123456789) – November 2013
<http://youtu.be/TMjnEFrrTjY>
7. Tom Hanks and Type 2 Diabetes – an evidence-based discussion I would like to have with Mr Hanks – January 2014
<http://youtu.be/jOxxHbdyXcg>
8. Bohemian Polypharmacy – February 2014
<http://youtu.be/Lp3pFjKoZl8>
9. Choosing Wisely – July 2014
<http://youtu.be/FqQ-JuRDkl8>
10. Eat Mediterranean – December 2014
<http://youtu.be/tfH6qSSTa90>